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ABSTRACT
CHARACTERIZATION OF P39, A Borrelia burgdorferi SPECIFIC PROTEIN.
Jill M. Troyer 
Old Dominion University 
and
Eastern Virginia Medical School 
1996
Director: Dr. Robert Ratzlaff
Borrelia burgdorferi, the causative agent o f Lyme disease, expresses a species 
specific, 39 kiloDalton protein of unknown function called P39. This protein is highly 
immunogenic and the presence of anti-P39 antibodies in patient sera is used as an 
indicator of B. burgdorferi infection. P39 is also a candidate for vaccine developement 
due to conserved expression of P39 among B.burgdorferi isolates. Since little is 
presently known about this important molecule, the present study was designed to 
characterize P39 and was carried out in six separate investigations. First, infectious 
and noninfectious isolates of B.burgdorferi were established in vitro, and the infectivity 
of each was assessed in a murine model. Second, the location of P39 within the 
spirochete was determined in infectious and noninfectious isolates by cell fractionation, 
and western blot analysis. A correlation was established between P39 localization and 
infectivity; infectious and noninfectious isolates localized P39 to both the outer 
envelope and inner membrane, but noninfectious isolates had increased levels of P39 
in the inner membrane and cytosol as compared to infectious isolates. Third, flow 
cytometry was used to determine if P39 expression is uniform throughout a population
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of spirochetes. Within a cloned population, organisms expressed similar levels o f P39 
on the outer surface. In contrast, uncloned populations displayed variable surface P39 
expression, and uncloned noninfectious B31, WCH1, and JD1 all expressed lower 
levels of P39 as compared to the respective infectious organisms. Fourth, detergent 
extraction studies were employed to determine the solubility of the P39 molecule. P39 
was shown to be hydrophobic in nature and the solubility o f the molecule was not 
altered in infectious or noninfectious isolates nor was it altered in different cell 
fractions. Fifth, P39 was immunoprecipitated from infectious and noninfectious 
isolates in an attempt to characterize molecules which associate with P39. P39 
coprecipitated with four molecules in all isolates, and six additional molecules 
common only to noninfectious isolates. Finally, in an attempt to determine if P39 
elicits immunopathological responses in an infected host, site directed DNA 
mutagenesis was used to inactivate the gene encoding P39. No viable P39 deletion 
mutants were obtained, thereby precluding any studies regarding immunopathology 
caused by P39. The results of this study demonstrate P39 is a hydrophobic, membrane 
associated protein, and is expressed by both infectious and noninfectious isolates. 
Furthermore, infectious and noninfectious isolates exhibited differences in P39 
localization, and coprecipitation.
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1I. INTRODUCTION
A. History of Lyme disease
Lyme disease is a vector-bome illness with symptoms ranging from mild 
arthritis to chronic cardiovascular and neurological abnormalities. It was first 
described as a clinical entity in 1977 by reason of a geographic clustering of children in 
Lyme, Connecticut thought to have juvenile rheumatoid arthritis (1,2). Due to the 
rural location of Lyme and distinct rashes which were identified as a  feature of the 
illness it was assumed that the disease was transmitted by an arthropod. It readily 
became apparent that Lyme disease was in fact a multisystem disorder that affected the 
nervous system and heart as well as the joints and skin. Epidemiological studies of 
patients suggested Lyme disease was caused by an infectious agent transmitted by ticks 
and identified the vector as belonging to the genus Ixodes (3). In 1982, almost five 
years after the search began, a previously unrecognized spirochete (thereafter titled 
Borrelia burgdorferi) was isolated from adult Ixodes scapularis ticks which were 
collected from an endemic focus of Lyme disease (4). Sixty one percent of I. 
scapularis collected in this area contained this newly discovered spirochete (4).
Patient sera was demonstrated to contain antibodies recognizing this organism, and in 
laboratory studies rabbits developed the characteristic Lyme rash after exposure to this 
spirochete via tick bite (4). Subsequently, the spirochete was actually isolated from 
several Lyme patients and the spirochetal etiology of Lyme disease was demonstrated 
conclusively (5). In recent years, there has been an increasing number o f reported 
Lyme disease cases. In 1994 alone there were greater than 13,000 reported cases of 
Lyme disease making it the most frequently diagnosed vector-bome disease in the 
United States (6), and consequently a disease of increasing importance.
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2B. Lyme Disease
1. Introduction
Humans who have been infected with B.burgdorferi may develop the 
pathology known as Lyme disease (7, 8, 9,10). This disease is a multisystemic 
disorder, most notably affecting the skin, joints, heart, and nervous system. The 
clinical course of Lyme disease can be roughly divided into three stages. The first 
stage occurs in the first days or months following exposure and is characterized by a 
migrating rash (erythema mi grans), fatigue, malaise, and flu-like symptoms. The 
second stage, occurring weeks to months after initial exposure, is characterized by 
swelling of joints (infiltration of monocytes into the joint space, synovial 
hyperplasia, intra- and peri-articular lesions), migratory musculoskeletal pain, as well 
as cardiovascular abnormalities (tachyarithmiaS, myopericarditis, atrioventricular 
conduction defect)(l 1), and neurologic complications (meningitis, encephalitis, optic 
neuritis, Bell’s palsy) (12,13). The third stage, occurring months to years post 
infection, is distinguished by severe arthritis, cartilage destruction, joint erosion, and 
chronic neurological disorders including numbness of limbs, facial palsies, heart 
palpitations, loss o f vision, and memory impairment (12,13, 14).
Borrelia burgdorferi has been divided into at least six genospecies including 
the following: B.burgdorferi sensu stricto, B.afzelii, and B.garinii. All three species 
can cause Lyme disease, and whether these species vary significantly in their 
physiology and ability to cause pathology is currently under scrutiny. European 
patients infected with B.afzelii or B.garinii have a preponderance of chronic skin 
manifestations as compared to U.S. patients infected with B.burgdorferi sensu stricto 
(15,16,17). In addition, arthritis is prevalent in B.burgdorferi sensu stricto infection, 
and neurological abnormalities are prevalent in both B.burgdorferi sensu stricto and 
B.garinii infections (17). These noted differences in pathology may be due to 
differences between the species of B.burgdorferi causing the disease. Alternatively the 
differences seen may be due to the genetic background and immune response of 
patients, or due to discernment of the doctor treating the patient. Further information
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3regarding the basic biology of the spirochete as well as the disease process itself must 
first be elucidated before such questions concerning strain variations and pathogenicity 
can be properly addressed.
2. Diagnosis
The symptoms of Lyme disease (i.e. myalgia, arthritis, myocarditis, and 
neurological abnormalities) mimic many other disorders (1,18,19,20,21). The 
progression of disease and the symptoms associated with it vary dramatically between 
individuals making a correct diagnosis difficult. Manifestations of Lyme disease often 
times are not recognized as being part of a single entity. Indeed, after identification of 
B.burgdorferi investigators began to implicate this spirochete as the causative agent of 
other previously recognized illnesses such as Bannwarth’s syndrome (a neurological 
disorder), and acrodermatitis (a skin disorder). Obviously, the most direct course for 
diagnosis would be isolation of B.burgdorferi from the patient. However, tissue 
culturing is expensive and requires considerable time and experience; therefore, for 
many laboratories it is impractical (22). In one study, only 6 of 154 tissue samples 
from patients have yielded spirochetes (23). Currently, serodiagnosis is the method 
used to assess B.burgdorferi infection (22,24,25,26). Indirect immunofluorescence 
assay (IFA) or enzyme linked immunosorbent assay (ELISA) are used as a primary 
screening method for serum samples. Samples which test positive for Lyme antibodies 
can be further characterized by a western blot analysis. The Center for Disease Control 
recommends a two test protocol for Lyme diagnosis; an EIA followed by a western 
blot for confirmation of positive results. A blot is considered positive if antibodies to 
two out of the three following bands are present: 39 kD (P39), 41 kD (flagellin), and 
21-24 kD(OspC) (27). These assays have their limitations as well. Since flagellin is 
expressed by other organisms, crossreactivity to this antigen is common for patients 
with other spirochetal illnesses. OspC migration in polyacrylimide gels is variable, as 
well as its expression among B.burgdorferi isolates, making identification difficult. In 
addition, during the first few weeks of infection, the humoral immune response to the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4organism may be weak resulting in a false negative in serologic assays. False positives 
can also result when patients are afflicted with other spirochetal illnesses. Another 
dilemma is a  curtailed immune response due to the administration of antibiotic 
treatment early in the infection. All o f these factors combine to make actual diagnosis 
of Lyme disease a challenge.
3. Treatment
Treatment of Lyme disease patients with high doses of oral antibiotics 
(tetracycline, amoxicillin, doxycycline, or in cases with neurological involvement, 
ceftriaxone) clears the infection and alleviates most symptoms o f the disease if 
administered early in the course of infection (12,14,28,29,30). If treatment is given 
later than six months after initial exposure, the symptoms are usually not completely 
reversible. Persistent symptoms may be caused by a process which is no longer 
antibiotic-sensitive (not due to the spirochete). For example, B. burgdorferi infection 
may trigger fibromyalgia, a chronic pain syndrome which is not antibiotic responsive 
(31). Since no identifiable toxins are expressed by the spirochete (32) the pathology 
observed in affected tissues may result from specific and nonspecific immunological 
responses to B.burgdorferi (19,33). Antibodies directed against myelin and myelin 
basic protein have been reported in patient sera (34,35). Research into the dynamics of 
specific and nonspecific immune responses of affected individuals should yield clues to 
the cause o f pathology.
4. Vaccine development
Due to difficulty in diagnosis and the occasional treatment failures, prevention 
of Lyme disease by vaccination has become an important alternative. The most studied 
vaccine candidate is a recombinant OspA molecule (rOspA). Active immunisation 
with rOspA or passive transfer of rOspA specific antibodies are protective against
B.burgdorferi infection in inbred strains of mice (36,37,38,39). Immunized mice are
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5protected from needle inoculation of infectious spirochetes (37) as well as natural 
infection via infected ticks (40). However, this vaccine affords protection only at the 
beginning stages of tick feeding before the spirochetes ever enter the host (41). The 
tick imbibes blood containing rOspA specific antibodies, and the antibodies destroy the 
spirochetes while they are still in the tick midgut. Within three to five days of the 
feeding, spirochetes can be found in tissues other than the midgut, such as salivary 
glands, malphigian tubules, central ganglion, and ovary (42,43,44). Once they are 
out of the tick gut they are no longer susceptible to the rOspA antibodies as the 
spirochetes decrease surface expression of the OspA molecule (41). In addition, this 
protection was only effective against a few isolates o f B.burgdorferi which share 
identical OspA sequences (45). This lack o f cross protection occurs when using other 
outer surface proteins as immunogens:OspB, OspC, OspD, OspE, and OspF (46,47, 
48). Because of this lack of cross protection afforded by these molecules, research is 
currently underway for other vaccine candidates.
C. The Lyme cycle
In nature, the B.burgdorferi population is maintained by cycling between 
hematophagous tick vectors (Ixodes spp.) and various vertebrate hosts such as mice and 
rats (49). The primary tick vectors Ixodes scapularis (northeastern U.S.), I.ricinus 
(Europe), and I. pacificus (western U.S.) all have a four stage life cycle: egg, larva, 
nymph, and adult. Ticks feed once during each stage (with the exception of the egg 
stage). If a tick does not feed it is not able to molt and continue development into the 
next life stage. Ticks feed by using their elongated, serrated chelicerae to cut into the 
epidermis of the host, ripping open blood vessels beneath the surface. The host is 
ordinarily unaware of this event as ticks inject various pharmacological agents into the 
wound site, via the hypostome, to prevent pain and inflammation from occurring.
These agents include prostaglandins and prostacyclins to prevent platelet aggregation, 
blood coagulation, and vasoconstriction; anti-histamines which decrease inflammation; 
and other unidentified substances which destroy bradykinin and block pain. Ticks also
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6secrete a substance produced in the salivary glands which acts as a  cement to secure the 
mouthparts of the tick into the wound site. Over a period of two to five days, ticks 
slowly imbibe a blood meal from the wound site. After engorgement, the process of 
detachment is initiated by secretion of an uncharacterized substance which dissolves 
the cement and allows the tick to exit the wound without damage to the chelicerae.
Ticks may become infected with B.burgdorferi after ingesting a blood meal 
from a host carrying the spirochete. In the wild, the infection rate o f ticks in endemic 
Lyme areas average 12-25% for nymphs, and 25-50% for adults (50,51). The average 
spirochetal burden is 2,000 5.6./tick in endemic areas (52). After feeding, ticks retain 
the blood meal in the midgut which acts primarily as a storage organ. Digestion of the 
blood occurs intracellularly by pinocytosis of cells lining the gut allowing spirochetes 
and other bacteria to remain undisturbed by enzymatic digestion. Spirochetes may 
remain in the midgut (42) or migrate out o f the mesothelium and into the surrounding 
tissue. The majority o f ticks (>80%) have spirochetes localized primarily in the midgut 
until after the next blood meal (4,42,44). For example, a larval tick becomes infected 
with its first blood meal and the spirochetes remain in the midgut until feeding 
commences in the nymph stage. Notably, 80% of infected, fed ticks contain spirochetes 
in the salivary glands (44). This is a significant figure considering ticks may then 
infect a host by secreting the spirochetes from the salivary glands directly into the 
wound site during attachment to the host (43,44, 53,54). Additionally, some scientists 
postulate that ticks may also regurgitate midgut contents, including spirochetes, 
directly into the wound during feeding (42). Spirochetes may persist and multiply 
throughout the life o f the tick. Therefore, if a tick is infected during the larval stage it 
has the potential to transmit B.burgdorferi to its subsequent hosts during both the 
nymph and adult stages.
After inoculation into the host via the bite o f an infected tick, the spirochetes 
migrate out of the wound site and invade the surrounding tissue. Spirochetes are 
motile in viscous mediums (55), and their dissemination throughout the host is due to a 
combination of passive transport via the circulatory or lymphatic systems, and active 
migration through the extracellular milieu. B. burgdorferi are capable of adhering to a
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7wide range of cell types such as human umbilical vein endothelial cells (56), tick cells 
(57) and human epithelial cells (58). B. burgdorferi has been shown to adhere with 
high specificity (via 19 and 20 kD proteins) to the proteoglycan decorin (decorin is 
bound to collagen fibers), but not to collagens type I or II (59). B. burgdorferi has also 
been shown to penetrate endothelial cell monolayers (60). One study demonstrated 
that within 24 hours organisms were able to penetrate the blood-brain barrier of rats 
when injected intravenously (61). However, the spirochetal adhesion molecules and 
the cell surface receptors involved in these processes have not been described
D. Animal models for Lyme disease
Several animal models, including rabbit, hamster, rat, and mouse, have been 
developed to study experimental and natural infection with B.burgdorferi. After 
inoculation with B.burgdorferi, rabbits develop a skin lesion similar to that found in 
Lyme patients but do not develop any other specific pathology. Hamster, rats, and 
mice, however, have proven valuable for following the dissemination of the spirochete 
after infection as well as immune responses, and pathology. These animal models only 
partially mimic the human disease. No animal model has yet been described which 
duplicates the presentation of the human disease. The murine model is the most 
frequently used system due to the knowledge surrounding the murine genetic and 
immune systems, and it has the advantage of being a natural reservoir for the spirochete 
in nature (36). Upon infection mice develop multisystemic infections and remain 
infected for well over a year (9,62). In addition, spirochetes can be transmitted to ticks 
feeding on the infected animals.
Xenodiagnosis is the term used for using ticks for detection of spirochetes in an 
infected animal. It is commonly used to assess the infectivity of newly isolated 
spirochetes. In general, transmission of spirochetes to feeding ticks is lower in 
inoculated mice than in naturally infected mice. Between 42-84% of ticks feeding on 
naturally infected hosts become infected, as compared to 6-35% for ticks feeding on 
experimentally inoculated hosts 14 to 100 days post inoculation (63,64).
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8Tissue culture is another form o f assessing the infectivity of B.burgdorferi. 
Spirochetes have been cultured from all o f the following mouse tissuesrbladder, spleen, 
kidney, liver, heart, eyes, brain, joint, skin and blood (7,8, 9, 10,36,37,62,65,66,67, 
68,69, 70,71, 72). The bladder has been demonstrated as being the most consistent 
source for isolation of B. burgdorferi in murine tissue culture (7,24,37,65,66,67,68, 
69, 73, 74). Recovery of spirochetes from 94% of bladders of infected mice as 
compared to 61% from spleen tissue, and even lower percentages for blood and kidney 
(67,69.). It is unclear whether this high recovery rate from bladder tissue is due to a 
possible spirochetal predilection for this organ, or due to an artifact of tissue culturing 
since the spirochetes may be sensitive to components present in the immascerated 
tissue of certain organs. Interestingly, B.burgdorferi gradually lose their infectivity 
during prolonged in vitro cultivation (7 ,9 ,24 ,65,66,67,69,73,75,76,77). This loss 
of infectivity is monitored by tissue culture, and xenodiagnosis.
Histopathology of Lyme disease in mice is wide spread; carditis and arthritis 
are common, and joints may become inflamed and swollen. Affected joints contain 
infiltrating polymorphonuclear leucocytes, immune complexes, and occasionally 
spirochetes. Though inflammation in various tissues is common, spirochetes are not 
always detected in or around areas of inflammation (78). This fact once again raises 
the issue of whether the spirochete or the immune response to the spirochete is 
responsible for tissue pathology.
Borrelia burgdorferi may persist in a host for years after the initial infection 
(62,68, 71, 79). The mechanism by which B.burgdorferi is capable of surviving the 
vigorous B and T cell responses generated in an immunocompetent host is currently 
unknown, and is under intensive scrutiny. Animals inoculated with spirochetes 
develop an early humoral response (<14 days) to OspA, OspB, P39 and flagellin. 
Naturally infected animals, including humans, respond with antibodies against the 20 
kD, 22 kD (OspC), 35 kD, P39, and 58 kD proteins o f B.burgdorferi, whereas few 
recognize flagellin, OspA, OspB until very late into the infection, and sometimes not at 
all (19,70,80,81). The spirochetes are susceptible to phagocytosis and complement 
mediated cytolysis (19,33, 82). Additionally, monoclonal antibodies specific for P39,
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complement (83). There is no evidence to indicate B.burgdorferi can vary surface 
antigens to escape immune response (84,85). However, nonspecific interactions 
between extracellular B.burgdorferi proteins and IgM antibodies have been reported 
(86), raising the possibility that nonspecific immune complexes may contribute to 
immune evasion by camouflaging the cell surface of the spirochete (86). Much 
remains to be learned regarding the spirochetes ability to survive an immune response. 
Indeed, specific factors required by the spirochete to maintain an infection in a 
mammalian host are currently unknown.
E. Biology of B.burgdorferi
The causative agent o f Lyme disease is the gram-negative spirochete, Borrelia 
burgdorferi (4). It was described as a new species o f the genus Borrelia on the basis of 
DNA-DNA homology and G + C content similarities (87). It was originally believed 
only a single species o f Borrelia caused Lyme disease. However, at least six different 
genospecies of B.burgdorferi sensu lato have now been recognized which are classified 
according to sequence differences in 16s rRNA genes and restriction fragment length 
polymorphism. Three o f these are B.burgdorferi sensu stricto (88,89), B.afzelii (90, 
91), and B.garinii (89, 92). The DNA homology among the different strains is 76 to 
100%. All three groups are found in Europe and Asia, but only B.burgdorferi sensu 
stricto has been isolated in the U.S (89). All three can cause Lyme disease but whether 
these strains vary significantly in their physiology or ability to cause pathology is 
currently under scrutiny.
Borrelia are the longest and thinnest of the spirochetes ranging in size from 0.2 
to 0.5 pm wide and 8 to 30 pm long (93). The cell is comprised of five basic structures: 
outer membrane, periplasmic space, flagella, inner cell membrane, and cytoplasmic 
compartment. The membrane composition of B. burgdorferi differs from that of other 
gram negative spirochetes in that it does not contain lipopolysaccharide (LPS) or 
phosphatidyethanolamine (94,95). In addition^B.burgdorferi have a substantial 
number of lipidated membrane proteins yet few transmembrane proteins in the outer
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envelope (96,97,98). B.burgdorferi expresses over 30 major proteins, but few have 
been well characterized. Several techniques have been used to characterize outer 
membrane proteins, including surface radioiodination or biotinylation of surface 
exposed proteins. From such experiments thirteen proteins have been identified: 22, 
24,29, 31,34,37,39,41,52,66,70,73, and a 93 kD molecule (99). Unfortunately, 
the further identification o f these surface molecules using monoclonals was not 
performed. Six lipoproteins (designated outer surface proteins or Osp) of unknown 
function have been identified using monoclonal antibodies: OspA, OspB, OspC, OspD, 
OspE, and OspF (46,75,100,101). However, the Osps are not exclusively located in 
the outer envelope as their name might suggest, lipidated Osps are also located in the 
inner membrane (102). The molecular weight of these molecules has been shown to 
vary between different isolates of B.burgdorferi (103,104) making the use of 
monoclonal antibodies essential in the identification of these molecules. Expression of 
the Osps are affected by changes in temperature (51,105,106). When a tick imbibes a 
blood meal the temperature in the gut increases. This increase in temperature results in 
a decreased surface expression of OspA and an increased surface expression of OspC, 
OspE, and OspF. This change is expression of these molecules is not rapid but occurs 
over several cycles of cell division (105). Early studies indicated that OspA and OspB 
may be important for adherence or invasion of host cells (107,108), and OspC for 
establishment of infection in a host. However, a mutant isolate which does not express 
OspA, OspB, OspC or OspD was shown to have decreased adhesion to human 
umbilical vein endothelial cells in vitro yet the infectivity of the organism was 
unaffected (109). Even though OspC is not critical for infectivity, it is theorized that 
OspC may be important in the migration of the spirochete from the midgut to the 
salivary gland (105).
Other Borrelia proteins include flagellin (41 kD), P39 (39 kD), two heat shock 
protein homologs (60 and 73 kD), a 93 kD and a 13 kD protein. Two proteins which 
appear conserved among all strains of B.burgdorferi are P39 and flagellin. P39 is an 
immunogenic protein of unknown function, and a member of a small family of proteins 
known as Borrelia membrane proteins (bmp). There are four members in this group:
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bmpA(P39), bmpB, bmpC, and bmpD. The function of these molecules is unknown 
but they are highly conserved among all three B.burgdorferi genospecies (110). The 
four genes are located on the chromosome and are arranged in the following 
ordenbmpD, bmpC, P39, bmpB. The bmpD has been shown to be monocistronic 
transcript (110). BmpC is also believed to be monocistronic (111), but P39 and bmpB 
are believed to constitute a single operon since P39 has a promoter region whereas 
bmpB does not (112). All contain basic charged residues followed by a hydrophobic 
region in the very N-terminus of the protein which is a typical signal sequence of 
membrane proteins (110,111,112). In addition, they all contain putative signal II 
peptidase site (LFIVAC) which suggests that they may also be lipoproteins yet no 
evidence of lipid modification has been shown (110,112). P39, in contrast to the Osps, 
is not differentially expressed in relation to temperature (105), and no P39-less mutants 
have ever been described in the literature.
Flagellin is the core protein unit of the spirochetes flagella. Borrelia have 
between 7 and 11 flagella that are sheathed and located between the inner and outer cell 
membranes, which is characteristic o f most spirochetes (93). Only a single flagellar 
protein constitutes the core structure of the B.burgdorferi flagella, unlike other 
organisms which have a complex of several protein subunits constituting the flagellar 
filament (113). Each flagellum is anchored to the inner membrane at one end of the 
spirochete and runs the length of the organism (93). In the middle of the spirochete the 
flagella from one end overlaps with flagella from the other end and forms a distinct 
bundle (114). The arrangement of the flagella dictates the helical shape of the cell and 
allows the spirochete to move in a spiraling motion. It has been shown that the 
spirochetes need a viscous medium, similar to the intercellular matrix of skin, in order 
to be motile (55). Spirochetes lose their motility in less viscous fluids such as blood, 
and appear to simply spin in place instead of progressing in any direction (55).
Growth of B.burgdorferi in vitro is slow and requires microaerophilic 
conditions, temperatures between 30 and 35°C, and a complex liquid medium known 
as Barbour-Stoenner-Kelly medium (BSK). The generation time is 12-24 hours (32)
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and Borrelia divide by forming a septum as opposed to division by constriction (93). 
As previously mentioned, the organisms gradually lose their infectivity during 
prolonged in vitro cultivation (7 ,9 ,24,65,66,67,73,75- 77). The loss is irreversible 
and occurs as early as the fifth in vitro passage or as late as the 10th passage. The 
direct reason for this loss is unclear, but investigators have documented a variety of 
changes that occur during culture including loss of DNA plasmids, changes in 
morphology, protein expression, and antigenicity (7,65,75-77,111, 115-117). Loss 
of extrachromosomal elements and subtle changes in antigenicity do occur in the 
zoonotic cycle, but any variation is limited compared with changes seen during in vitro 
cultivation (111). Investigators have tried to identify factors responsible for the 
infectivity of the organism by comparing whole cell sonicates of infectious and 
noninfectious organisms and have documented specific DNA plasmids and proteins 
which are no longer present in some noninfectious isolates (65,68,75,76,115-117). 
However, the loss o f plasmids or protein expression is not consistent among isolates 
which have lost infectivity. This raises the possibility that infectivity is dependent 
upon a number of factors; the loss of any one factor results in loss of infectivity. To 
date, no factors critical to the infectivity of the organism have been identified.
The genetic makeup of B.burgdorferi consists o f a 1000 kilobase chromosome 
and has a cytosine/guanine ratio of 27 to 30%. In addition to the chromosome, four to 
nine circular and linear plasmids (linear plasmids are unique to the genus Borrelia) 
ranging in size between 16- to 175-kilo bases have been identified in isolates of 
B.burgdorferi (49,65,118,119). The spirochetes are clonal and show no evidence of 
lateral gene transfer between organisms (91). Therefore, all genes within a strain will 
share a common evolutionary history in the absence of recombination. In addition, no 
antigenic variation involving altered expression of proteins by genetic modification, 
conferring a selective advantage to the organism has been documented for 
B.burgdorferi. Fifteen other Borrerlia species, such as Borrelia hermsii the causative 
agent of relapsing fever, exhibit antigenic variation by changing the expression of 
immunodominant, surface exposed, lipoproteins known as Variable Major Proteins or 
VMP (77). The genetic switch occurs between two linear plasmids, one carrying the
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silent VMP gene and the other carrying the expressed VMP gene proceeded by a 
promoter. The silent gene physically replaces the active gene during genetic 
recombination, and the formerly active gene is lost. Borrelia burgdorferi's  close 
relation to these organisms, and possession of linear plasmids, led researchers to 
investigate antigenic variation in the Lyme disease spirochete. Initially data regarding 
the discrepancy between protein profiles and antigenicity of spirochetes recovered from 
inoculated hosts versus the profiles of the original inoculum (usually an uncloned 
population) was misinterpreted as possible antigenic variation (77,104). However, 
subsequent analysis using cloned organisms revealed the inaccuracy of the conclusion.
F. Discovery of P39
P39 was initially described in an attempt to identify B.burgdorferi specific 
antigens that could enhance the specificity of diagnostic assays. P39 was shown to be 
consistently immunogenic in experimentally and naturally infected mice (24,74) and 
one hundred percent (n=94) of confirmed Lyme patients tested produced antibodies 
specific for P39 (74). More importantly, no anti-P39 antibodies were found in control 
sera collected from 25 patients with other spirochetal illnesses such as syphilis, and 
relapsing fever, or amyotrophic lateral sclerosis (an auto immune disorder) or normal 
individuals (74). It was also demonstrated that P39 expression is conserved among 
North American and European isolates (24), a trait not shared by several other 
B.burgdorferi proteins such as OspA, OspB, and OspC (103, 104). As a result, the 
immunogenicity, species specificity, and conserved expression of P39 have made it an 
indispensable tool for the diagnosis Lyme disease. Currently microtiter plates coated 
with E.coli expressing recombinant P39 are used in screening of sera for Lyme disease 
(General Biometrics, SanDiego, CA). Purification of P39 does not enhance the 
effectiveness of this assay, therefore the Ecoli expressing P39 is used.
Two different monoclonals were developed for further study of P39. The first 
monoclonal was developed using recombinant P39 antigen. The gene encoding P39 
was cloned in a pBluescript vector designated pSPR33. This recombinant P39 antigen 
was expressed in E.coli and was injected into Balb/c mice. The monoclonal antibody
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D1C9 was obtained from this experiment and subsequently shown to be specific for 
B. burgdorferi P39 antigen by western blot analysis (24,74). The epitope for DIC9 has 
not yet been mapped, but the monoclonal has a high titer and is commonly used in our 
laboratory at a 1/250 or greater dilution for IF A or ELISA. Another monoclonal to 
P39, Hkmy, was developed by injecting B. burgdorferi into mice and screening 
hybridomas for reactivity to P39. However this monoclonal is of very low titer and 
must be used undiluted. This monoclonal was not used in the present study due to the 
weak reactivity to P39. Accurate detection and quantitation of P39 was necessary for 
this study and the weak reactivity of this antibody would not allow such analysis.
The location and function of P39 within the organism is unknown. However, a 
sequence analysis of the cloned P39 gene revealed the coding sequence to be 1020 
nucleotides in length (112) and the deduced amino acid sequence has the highest 
homology (27%) with TmpC, a  putative membrane protein of the spirochete 
Treponema pallidum (112) also of an unknown function. The amino terminus of P39 
contains charged residues followed by hydrophobic residues consistent with a signal 
peptide sequence, and the amino acids from residues 14-18 are consistent with a signal 
peptidase H site (112). These observations suggest that P39 may be associated with 
either the outer membrane or the inner membrane of B. burgdorferi (112). A study 
attempting to locate P39 in whole cell Borrelia using immuno-electron microscopy 
(EM) with monoclonal antibody Hkmy gave some evidence for membrane as well as 
cytoplasmic localization (120). However, most EM studies of P39 have been 
unsuccessful (this lab, Schwan unpublished data) making confirmation of this finding 
difficult.
G. Focus of the present study
1. Rational
P39 is an important molecule in respect to the diagnosis of Lyme disease, yet 
little is currently known about the molecule. For instance where it resides, what it 
associates with in the cell, and if  it is related to the infectivity of the organism, or a
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cause in the pathology of Lyme disease are all unknown. The objective o f the present 
study is to more fully understand the physical and biochemical nature o f the P39 
molecule expressed by B.burgdotferi. If the molecules responsible for B.burgdorferi 
infectivity or pathology in Lyme disease are elucidated, more effective treatments and 
therapies for Lyme disease patients would be forthcoming.
2. Specific Aims
1. The first objective was to determine where P39 resides within infectious and 
noninfectious spirochetes and determine if  there is a correlation between P39 
localization and infectivity. Whole cell spirochetes were separated into three 
subcellular fractions: outer envelope, innermembrane, and cytosolic fractions. Cell 
fractions were analyzed by SDS-PAGE, silver stain and western blot to determine the 
protein composition o f each fraction. This procedure was performed on both infectious 
and noninfectious isolates, allowing for correlation between P39 localization and 
infectivity of the organism.
2. The next aim was to determine if P39 surface expression was uniform 
throughout a population of spirochetes. Since several of the isolates used in the study 
were uncloned populations, it was important to determine the variability in P39 surface 
expression within an isolate. Both cloned and uncloned populations of B.burgdorferi 
were analyzed by flow cytometry after staining with a monoclonal specific for P39.
3. The next aim was to determine the solubility of P39 and determine if the 
solubility of P39 differed in infectious and noninfectious isolates. Detergent extraction 
techniques were employed to separate hydrophobic and hydrophilic components of cell 
fractions from infectious and noninfectious isolates, and they were analyzed by SDS- 
PAGE and western blot.
4. The next aim was to determine what molecules associate with P39, and if 
those molecules are different in infectious and noninfectious isolates. Whole cell 
sonicates were subjected to immunoprecipitatioh using a monoclonal specific for P39. 
The immunoprecipitants from infectious and noninfectious isolates were then analyzed 
by SDS-PAGE and silver staining.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
16
5. The final aim was to assess the role o f P39 in the infectivity o f the spirochete 
and in the pathology of Lyme disease. The cloned P39 gene was mutated by deletion 
of a 300 bp fragment from the front of the reading frame. The resulting mutant P39 
gene was used to transform low passage infectious organisms in order to create 
B.burgdorferi P39-less mutants. Using this approach, one can specifically determine if 
expression of P39 is required for B.burgdorferi viability, infectivity, or if  P39 is 
involved in the pathology of Lyme disease.
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LI. MATERIALS AND METHODS
A. Materials
1. Borrelia isolates
Characteristics of P39 (localization, etc.) were investigated by comparing 
various infectious and noninfectious isolates of B.burgdorferi. All isolates used in this 
study are members of the group B.burgdorferi sensu stricto originally isolated from 
Ixodes scapularis ticks (4). Isolate CN40 is a clonal population derived from isolate 
N40 after the fourth in vitro passage (62). N40 was originally isolated in 1988 from a 
tick in Westchester County, New York (121). CN40 is the only population of
B.burgdorferi known to retain infectivity during in vitro culture. This isolate allows 
observation of changes in B.burgdorferi which are due to in vitro culture and not 
related to loss of infectivity. CN40 was kindly provided by Dr. Stephen Barthold (Yale 
University, New Haven, CT).
All remaining isolates are uncloned populations, and serve as model isolates 
which lose infectivity after in vitro culture. These isolates include B31, WCH1, and 
JD1. Isolate B31 (purchased from American Type Tissue Culture Collection ATCC 
35210) is the prototype B.burgdorferi isolate, and was recovered from a pool of adult 
Ixodes scapularis from Shelter Island, NY by Willy Burgdorfer in 1982 (4). Isolate 
WCH1 was isolated from adult Ixodes scapularis ticks from Westchester County, N Y 
in 1986. Isolate JD1 was isolated from nymphal Ixodes scapularis ticks collected in 
Ipswich, MA in 1987 (53). Both JD1 and WCH1 were a gift from Dr. Joseph Piesman 
(Center for DiseasfrControl, Fort Collins, CO) for use in this study.
Nine additional clones were generated from WCH1 by the author by limiting 
dilution, and analyzed by flow ctytometry (see below).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
18
2. Ticks
Laboratory raised, spirochete-free Ixodes scapularis nymphal ticks were a gift 
from Dr. Joseph Piesman (Center for Disease Control, Fort Collins, CO), and were kept 
in mesh covered glass vials and placed in a climate controlled incubator (26°C ± 
l°)with 92 ± 2% relative humidity and 14:10 light dark cycle.
3. Mice
Six to 12 week old, female B6CBAF1/J mice (Jackson Laboratory, Bar Harbor, 
ME) were used for the infectivity assay. Prior to the assay, daily care for the animals 
were provided by the Animal Facility at Old Dominion University. All treatment of 
the animals was approved by the University LACUC and was in accordance with the 
Federal Guide for the Care and Use of Laboratory Animals.
4. Medium
Borrelia burgdorferi isolates were cultured in liquid BSKII or BSKH medium 
supplemented with 6% rabbit serum (Pel Freeze Biologicals, Rogers, Arkansas) and 
antibiotics (phosphomycin 100 mg/ml and rifampicin 50 mg/ml, SIGMA chemical 
company, St. Louis, MO). For infectivity studies cultures were grown in 15 ml screw 
cap vials, and for fractionation studies isolates were grown in three 30 ml culture 
flasks.
5. Monoclonal antibodies
Monoclonal antibodies (Mab) used in this study were as follows: Mab D1C9, 
specific for P39 was provided by Dr. Tom Schwan (Rocky Mountain Laboratories, 
National Institute of Allergy and Infectious Diseases, Hamilton, MT). Mab H5332 
specific for OspA, Mab H6831 specific for OspB, Mab H9724 specific for flagellin, 
and H4825 specific for B.hermsii were provided by Allen G. Barbour (Health Science 
Center, Univ. of Texas, San Antonio, TX). Goat anti-mouse IgG fluorescein- 
isothiocyanate conjugate (FITC) was purchased from Kirkegaard Perry Labs, 
Gaithersberg, MD, as well as peroxidase labeled goat anti-mouse IgG.




The pBluescript plasmid pSPR33 contains an 6.3 kb insert encoding P39 and a 
second open reading frame (ORF2) (24, 74). The plasmid was given to this lab in a 
glycerol stock by Dr. Tom Schwan (Rocky Mountain Laboratories, National Institute 
of Allergy and Infectious Diseases, Hamilton, MT).
b. pCHHO
The plasmid pCHl 10 contains an insert (3.6 kb) encoding the entire Beta 
galactosidase gene (LacZ). LacZ metabolizes B-galactose into glucose and lactose 
molecules. The plasmid was given to this lab by Dr. Timothy Bos (Eastern Virginia 
Medical School, Norfolk, VA).
7. PCR Primers
The primer sequences were derived from a randomly cloned, chromosomal 
DNA of isolate B31. The sequence is specific for B.burgdorferi and is not present in 
other Borrelia species (122, 123,124,125). Initially described by Rosa and Schwan 
(123,125), this genomic sequence has been analyzed by several databases and no 
homology has been found between the deduced amino acid sequence and any known 
proteins. Regardless, the value of this sequence lies in its conservation among 
B.burgdorferi and its absence in other Borrelia species. In addition, it is a 
chromosomally located gene sequence as opposed to a plasmid encoded gene; this is an 
important feature since plasmids are heterogenous among isolates and can be lost 
during in vitro culture.
Forward primer sequence: CGAAGATACTAAATCTGT
Reverse primer sequence: GATCAAATATTTCAGCTT
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The primers were synthesized at the Core Molecular Biology facility at Eastern 
Virginia Medical School.
8. Buffers
Sodium bicarbonate buffer: 14 mM Na2C03, 34 mM NaHC03, pH=9.6 
Phosphate buffered saline (TBS): 10 mM NaCL, 8 mM Na2HP04, 8 mM NaH2P 04 
pH=7.4
PBS-Tween: PBS supplemented with 0.05% Tween 20 detergent (Sigma). 
PBS-Tween/BSA: PBS-Tween supplemented with 1 mg/ml Bovine Serum Albumin 
(BSA, Sigma).
PBS/MeCl?: PBS supplemented with 5 mM MgCl2 pH=7.8
Ketamine/xvlazine solution: xylazine 20 mg/ml (Butler, Columbus, OH) and ketamine 
62.5 mg/ml (Aveco Co., Fort Dodge, IA)
Lysis buffer: PBS, 1% SDS, and 0.1 mM proteinase K
2x sample buffer: 1.25 mM Tris[hydroxymethyl]amino-methane (Tris), 20% glycerol, 
4% SDS, 10% 2-mercaptoethanol, H20, pH=6.8
Coomasie fixing solution: 40% methanol, 10% acetic acid, 0.5% coomasie brilliant 
blue
Destaining solution: 40% methanol, 10% acetic acid solution 
Silver equilibration solution: 0.5% silver nitrate in water 
Development solution: 10% sodium carbonate,-0.05% formaldehyde in water 
Stop solution:!% glacial acetic acid in water
Reducer solution: 0.6% Potassium ferricyanide, 1.3% Sodium thiosulfate, 0.2% 
Sodium carbonate
Electroporation solution fEPSk 272 mM sucrose and 15% glycerol.
TE buffer: 50 mM Tris, 50 mM EDTA, pH=8.0
10x blunt end buffer: 100 mM Tris pH=7.5,0.5 mM EDTA, 50 mM MgCl2
NET buffer: 150 mM NaCl, 5 mM EDTA, 50 mM Tris pH=7.5,0.05% NP-40
Resuspension Buffer P1: 100 pg/ml RNase A, 50 mM Tris/HCL, 10 mM EDTA,
pH=8.0
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Lvsis Buffer P2: 200 mM NaOH, 1% SDS
Neutralization Buffer P3: 3.0 M potassium acetate KOac, pH=5.5
Equilibration Buffer OBT: 750 mM NaCL, 50 mM MOPS, 15% ethanol, pH=7.0,
0.15% Triton X-100
Wash BufferOC: 1.0 M NaCL, 50 mM MOPS, 15% ethanol, pH=7.0 
Elution Buffer OF: 1.25 M NaCl, 50 mM Tris/HCL, 15% ethanol, pH=8.5
B. Methods
1. Establishment of infectious and noninfectious populations of Borrelia 
burgdorferi
Noninfectious isolates were generated from infectious WCH1 passage 5 (p5), 
JD1 passage 3 (p3), and B31 passage 6 (p6) by culturing each in vitro for 
approximately 3 months. The Borrelia were grown in screw cap vials with 15 ml of 
BSKII incubated at 33°C, and were passed once a week by transferring 5% of spent 
culture to a new tube of fresh media (equivalent to one passage). Isolates were 
routinely analyzed by dark field microscopy and motility, activity, and general 
appearance were noted. An isolate was designated high passage after passage 15. 
Passage fifteen was considered a sufficient end point for high passage since most 
isolates lose infectivity by the tenth passage. In this study, isolate CN40 was cultured 
as described above and harvested at p9 and p22 . Isolate CN40 is unique in its ability 
to retain infectivity during in vitro culture and was used in this study as a control for 
changes induced by in vitro culture which have no affect on infectivity. All isolates 
were counted using Petroff-Hauser bacterial counting chamber (Baxter Scientific, 
McGaw Park, 111.). Each isolate was counted three times and the values averaged. The 
averaged value was recorded as the concentration of spirochetes in culture.
The method used to assess infectivity of B.burgdorferi has been previously 
described (7,67,68). Briefly, low passage (p< 10) and high passage (p>15) isolates 
were harvested by centrifugation at 10,000 x g for 10 min at 4°C. Spent media was 
decanted and cells were washed to remove all traces of media by resuspending the cell
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pellet in 10 ml of PBS/MgCl2 and repeating the centrifugation step. This washing step 
was repeated once more and the final cell pellet was resuspended in 5 ml of 
PBS/MgCl2 The Borrelia were counted on a Petroff -Hauser chamber and adjusted to 
106 organisms per ml. Viability of washed organisms was confirmed by re-inoculation 
of 20 pi into 2 ml of BSKII media.
For each isolate, two B6CBAF1/J mice received an intraperitoneal (i.p.) 
injection o f 100,000 spirochetes. After 15 days, mice were sedated with a  50 pi 
injection of ketamine/xylazine solution, and 25 Lscapularis nymphs were allowed to 
feed on the mice for xenodiagnosis. Mice were then placed in individual chambers 
with wire mesh flooring. The chambers were elevated over collecting trays lined with 
double sided tape which served to retain the ticks once they detached from the mice 
after feeding. The mice were kept in these cages for five days. The engorged nymphs 
were collected and kept in glass vials for 6 days at room temperature to allow Borrelia 
to multiply. Using a sterile razor blade, ticks were dissected and gut contents were 
smeared onto a glass slide and processed by immunofluorescent antibody assay (IFA) 
for detection of Borrelia as described below.
Mice were sacrificed by cervical dislocation 21 days post-inoculation and the 
bladders were surgically removed and divided into two equal halves. One half was 
cultured in BSK-II media (tissue culture) and the other half was frozen in BSK II media 
at -80°C until needed for further analysis by PCR as described below. An isolate was 
considered infectious if spirochetes were recovered from mouse tissue, detected in tick 
smears, or detected by PCR in tissue samples. All negative results were confirmed by 
repeating the experiment.
For tissue culture, one half of a mouse bladder was placed in an eppendorf tube 
containing 500 ul BSK II media. The tissue was mascerated for one minute using a 
sterile pestle. The mascerated tissue and media was divided into two aliquots and each 
aliquot was added to a 10 ml tube of BSK II. Cultures were incubated at 33°C, and 
were viewed by dark field microscopy every 3-4 days for detection of B.burgdorferi. 
The presence of the spirochete was confirmed by immunofluorescence assay as 
described below.
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a. Immunofluorescence assay (IFA)
Culture supernatants (20 pi) or tick guts (each tick analyzed individually) were 
smeared onto glass slides, air dried for 10 minutes, then fixed with acetone 
(Mallinckrodt Inc., Paris, KY) for 20 minutes at room temperature. The slides were 
rinsed 3 times in PBS and 10 pi o f undiluted monoclonal antibody (Mab) H5332 
specific for B.burgdorferi outer surface protein A (OspA) was added to each slide and 
incubated for 1 hour in a humid, dark chamber at 37°C. The slides were rinsed 3 times 
in PBS and 10 ul of goat anti-mouse IgG fluorescein-isothiocyanate conjugate (1/40 in 
PBS) was added to each slide and incubated for. 1 hour at 37°C in a humid, dark 
chamber. The slides were rinsed 3 times in PBS and frozen at -20°C until viewed by 
fluorescence microscopy using an Olympus AH-2, Vanox model T microscope.
OspA was selected as the target antigen due to the high surface expression of 
this antigen in all the isolates used in this study (53,126). IFA staining of OspA gives 
very high fluorescence and is readily detectable. Other antigens, such as P39, are not 
readily detectable by IFA presumably because the epitope is fixative sensitive. 
Fluorescent intensity was monitored and given a rating: - (no fluorescence) or + 
(fluorescence equivalent to a positive control slide containing B31 spirochetes). Tissue 
cultures were designated positive if one or more spirochetes were detected by IF A, and 
negative if no spirochetes were detected by IFA.
b. Polymerase chain reaction (PCR)
PCR was used to detect B.burgdorferi DNA in bladder tissue samples taken 
from mice using methods previously described (122,123,124,125). Frozen tissues 
(one half of the total organ) were thawed at room temperature then rinsed in sterile PBS 
and minced with a sterile scalpel. The minced tissues were suspended in 1 ml of lysis 
buffer and incubated at 37°C for 24 hr. Samples were then extracted twice with 1:1 
volume of phenol/chloroform followed by a final 1:1 chloroform extraction. The DNA 
was precipitated by the addition o f 1 ml of ice cold 100% ethanol and 10 pi of 3M
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sodium acetate. The samples were incubated at -20°C overnight and DNA was 
pelleted by centrifugation at 14,000 rpm for 15 min at 4°C. The pellets were air dried 
and resuspended in 50 pi sterile water. Samples were heated to 100°C for 5 min to 
inactivate proteinase K. The DNA concentration was determined by OD 260. Each 
PCR reaction contained 500 ng of template DNA, 5 pi o f each primer (10 pM), 10 pi 
of dNTP (1.25 mM), 1 pi o f Taq polymerase, 10 pi of lOx PCR buffer, and a final 
magnesium concentration of 1.5 mM in a 100 pi volume. Controls included the 
following: a water control for PCR contamination, 500 ng of DNA extracted from 
uninfected mouse tissue spiked with lpg, 10 ng, or 10 pg of B.burgdorferi template 
DNA. After an initial 5 min denaturing step at 94°C, 30 cycles were executed as 
follows: denature 1 min at 94°C, anneal 30 sec at 37°C, and extension 2 min at 72°. 
PCR was performed on an automated thermal cycler (Perkin Elmer). Ten microliters 
of each PCR reaction was electrophoresed on a 0.8% agarose gel followed by staining 
with ethidium bromide to detect DNA bands.
2. Protein localization in B.burgdorferi
a. Cell fractionation of Borrelia burgdorferi
Spirochetes were collected from culture by centrifugation at 10,000 x g at 4°C 
for 10 min and adjusted to 35 x 106 organisms/ml in PBS. Spirochetes were not 
washed further due to the fragile nature o f the outer envelope (127). The outer 
envelope was removed by adding sodium dodecyl sulfate (SDS) to a final 
concentration of 0.03% in a 10 ml volume of spirochetes, followed by incubation at 
room for 15 min. During this step the outer envelope is solublized and remains in the 
aqueous phase. The solution was centrifuged at 15,000 x g for 90 min to pellet the 
intact protoplasmic cylinders (intact cell without outer envelope). The supernatant 
containing the outer envelope fraction (OE) was removed and the protoplasmic 
cylinders were resuspended to the original volume in PBS thereby retaining equivalent 
concentration of spirochetes. The protoplasmic cylinders were then sonicated on ice 
for 3 minutes in 20 second pulses to break apart the cell. The sonicate was centrifuged
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
25
for two hours at 138,000 x g at 4°C to separate the inner membrane fraction and the 
cytosolic fraction (pellet and supernatant respectively). The cytosolic fraction (CY) 
was removed and the inner membrane fraction (IM) was resuspended in PBS to 
original volume to maintain equivalence. All fractions were stored at -20°C. A media 
sample was run through the fractionation procedure and 8 ul were included on gels 
developed by silver staining (media control).
b. Protein assay of cell fractions
The protein concentration of each cell fraction was determined using Micro 
BCA Protein Assay Kit (Pierce, Rockford, IL ). Standards were tested in duplicate at 
the following concentrations: 0.5, 1 ,2 ,4 ,8 ,12 ,16 , and 20 |ig/ml. Each sample was 
tested in triplicate at the following volumes: 5 ul of outer envelope, 10 ul o f inner 
membrane, and 20 ul of cytosolic fraction. Due to the low protein content o f the inner 
membrane and cytosolic fractions, a larger sample size was needed to assess the protein 
concentration within the range of the assay (0.5 ug/ml).
c. SDS-PAGE
All reagents were prepared according to the method of Laemmli (128). The cell 
fractions collected from isolates were subjected to SDS-PAGE. Equal volumes (8 
microliters) o f each cell fraction (OE, IM, CY), representing material derived from 107 
organisms, were added to 20 microliters of 2x sample buffer. The samples were boiled 
for 1 min then loaded onto a SDS-PAGE 12-15% gradient gel and electrophoresed at 
250 volts for approximately 3.5 hours. Gels were then processed by silver staining or 
western blot as described below.
d. Western Blot
The electrophoresed proteins were transferred to 0.22 micron nitrocellulose 
paper (Micron Separations Inc., Westboro, MA) via western blot at 14 volts overnight. 
The blot was soaked for 1 hour in 1/20 milk diluent (KPL) in PBS-Tween 20. 
Spirochetal antigens (P39, Osp B, Osp A, and flagellin) were detected using the
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following monoclonal antibodies: D1C9 (anti-P39,1/250), H6831 (anti-OspB, 1/1500), 
H5332 (anti-OspA, 1/2000), H9724 (anti-Fla, 1/100). Blots were incubated with the 
monoclonal antibodies for 1 hour on a rotating plate. The blots were rinsed 4 times 
with PBS/Tween 20, then incubated with a 1/2000 dilution of goat anti-mouse IgG 
peroxidase (KPL) conjugate for 1 hour on a rotating plate, followed by four successive 
washes with PBS/Tween 20. Blots were developed with TMB peroxidase substrate 
(KPL) for 5-10 min followed by one thorough wash with distilled water to stop the 
reaction. Blots were scanned by a LKB 2222-20 Ultroscan laser densitometer 
(Pharmacia, Bromma, Sweden) for quantitation o f reactive proteins in each fraction. 
Data was analyzed by regression analysis.
e. Silver Stain
Gels were silver stained using Sigma’s Silver Stain Kit AG-25 as directed by 
the manufacturer. Gels were placed in 300 ml o f silver equilibration solution for 30 
min with constant agitation. The silver solution was discarded and the gels quickly 
rinsed in water for 10-20 seconds. Developer solution was then added to the gels in 
two successive washes of 150 ml each. The development of bands was aborted by 
washing the gels in Stop solution for 5 min, followed by three washes in water for 10 
min each. Gels were then placed for 20 seconds in 300 ml of Reducer solution in order 
to reduce background staining. Gels were subsequently washed three times in water 
for 10 min each rinse. Gels were then photographed for preservation of the data. 
According to the manufacturer, silver staining can detect as little as 50 ng of protein, 
but the intensity of staining depends upon the characteristics of each individual protein 
(129,130).
3. Flow Cytometry
a. Generation of clonal populations of WCHI
Clones o f isolate WCHI p5 were generated by limiting dilution (131). Cells 
were counted using a Petrof-Hauser chamber, and one ml of culture was serial diluted
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10-fold in BSK II media until a concentration o f approximately one B.burgdorferilxal 
was obtained. Fifty cultures (one ml each) were grown as described above and checked 
every week using dark field microscopy for detection of B.burgdorferi. A total of nine 
clones were obtained from the 50 cultures. Clones were designated WCHI clone 1, 
clone 2, etc. through clone 9 and were harvested at p6 and p i7. Clone 4,7, and 8 were 
discarded because o f fungal contamination.
The remaining clones were analyzed by ELISA for differences in P39 
expression using the following procedure: Whole cell antigen was prepared by 
harvesting organisms from a 30 ml culture (passage 6) by centrifugation at 10,000 x g 
for 10 min and adjusting in PBS to a cell density of 0.25 OD at 650 nm (approximately 
106 org./ml). Sonicated antigen of these six clones was prepared by sonicating on ice 
one ml of whole cell suspension four times for 30 seconds at 30 W (Sonifier cell 
disrupter, Branson Sonic Cc., Danbury, CN). Whole cell and sonicate preparations of 
WCHI p.5, and WCHI clones at p.6 were plated in duplicate on 96 well microtiter 
plates (Falcon 3911 assay plates, Becton, Dickinson Labware, Oxnard, CA) using 
sodium bicarbonate buffer. The final volume in each well was 100 ul. Plates were 
covered with saran wrap and stored at 4°C overnight. Plates were washed three times 
in PBS-Tween. Each well was blocked using PBS-Tween/BSA at a final volume of 
100 ul/well. Plates were incubated with constant agitation 0.5 hour. Plates were 
washed three times in PBS-Tween. Antigen was detected using Mab D1C9 (specific 
for P39) at 1/1000 in PBS-Tween/BSA. Plates were incubated with constant agitation 
for 0.5 hour, then washed three times in PBS-Tween. Bound antibody was detected 
using peroxidase conjugated Goat anti-Mouse IgG at 1/800 in PBS-Tween. Plates 
were incubated with constant agitation for 0.5 hour. Plates were washed three times in 
PBS-Tween. TMB Peroxidase substrate (KPL) was added at a final volume of 100 
ul/well. After five minutes, plates were read on a spectrophotometer at 650 nm. Two 
wells containing no antigen were included on each plate. The readings obtained in 
these two “blank” wells were averaged and this value, designated nonspecific 
reactivity, was subtracted from the values obtained for whole cell and sonicate antigen.
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The adjusted values of each duplicate sample was then averaged and used as the final 
value of absorbance at 650 nm. Interassay sample variation was less than 0.2 units of 
absorbance.
b. Flow cytometry analysis of cloned and uncloned B.burgdorferi
Whole cells were assayed by flow cytometry to determine if outer surface 
expression of P39, OspB, and OspA were uniform among cloned, uncloned, infectious, 
and noninfectious populations o f B.burgdorferi. Two hundred microliters of 
uncloned, whole cell WCHI, JD1, and B31, as well as the cloned populations of CN40, 
and WCHI clone 1 were incubated with 20 ul of undiluted anti-OspA, anti-OspB, anti- 
Fla, or anti-P39 for 30 min at room temp. Cell were pelleted by centrifugation at 
14,000 rpm for 1 min, the supernatant was aspirated, and the pellet resuspended in 200 
ul of PBS. Five microliters o f goat anti-mouse IgG fluorescein-isothiocyanate 
conjugate (1/40 in PBS) was added to each sample. All samples were covered with foil 
to protect from the light. Samples were incubated for 30 min at room temp, washed 
twice in PBS, then resuspended to 500 ul. PBS. Samples were filtered through a 0.44 
micron filter to remove any particulate debris, then read on a FACScan single laser 
flow cytometer (Becton Dickinson, Mountain View, CA). Settings were as follows: 
0.250mW at 430 volts, 5000 organisms read for each sample. The control for 
nonspecific staining was B31 incubated without primary antibody, but with the 
secondary antibody.
4. Triton X-114 phase partitioning of hydrophobic proteins
Triton X-l 14 phase partitioning of Borrelia proteins (132,133,134,135) was 
performed in order to determine the soluble character of P39. Two hundred microliters 
of whole cell sonicate or cell fractions from CN40 or B31 were mixed with 600 ml of 
TE buffer and Triton X-l 14 (SIGMA) was added to a final concentration of 1%. The 
samples were placed on ice for 15 minutes and inverted occasionally. The samples 
were then warmed to 36°C for 5 min. When the solutions became cloudy, the samples 
were centrifuged at 2,500 rpm for 3 min in order to separate the phases. The aqueous
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phase was transferred to a new tube. All detergent soluble phases were washed three 
times by resuspension in TE and Triton X-l 14 (final concentration of 1%), followed by 
incubation on ice for 15 min, incubation at 36°C for 5 min, and centrifugation.
Aqueous phases were washed 3 times by adding Triton X-l 14 to a final concentration 
of 2% (to ensure complete removal o f hydrophobic molecules), followed by incubation 
on ice for 15 min, incubation at 36°C for 5 min, and centrifugation. The final aqueous 
and detergent soluble fractions were then acetone precipitated with 2 volumes of cold 
acetone and incubated overnight at 4°C. The samples were centrifuged at 14,000 rpm 
for 10 min at 4°C. The pellets were air dried for 20 min and resuspended in 100 ml of 
lx  Laemmli sample buffer. Prior to loading onto a SDS-PAGE, the samples were 
boiled for 5 min then centrifuged for 1 min at 10,000 rpm to pellet any insoluble 
material. Thirty microliters were loaded onto a 12.5% gel.. Electrophoresis was 
conducted for 3 hours at 250 volts. The gels were subjected to western blot and 
developed using antibody D1C9 specific for P39 as described previously.
5. Immunoprecipitation
Immunoprecipitation of P39 from whole cell sonicates of infectious and 
noninfectious spirochetes was performed. Two hundred microliters (approximately 7 x 
106 organisms) of whole cell sonicate were precleared by adding 450 ml of NET 
buffer, 1 mg/ml BSA, and 50 pi of prewashed Pansorbin. The mixture was incubated 
for 1 hr at 22°C, followed by centrifugation at 10,000 x g for 1 min. The supernatant 
was removed and placed in a clean eppendorf tube. Ten microliters of monoclonal 
antibody D1C9 (specific for P39), or an isotype matched control, Mab H4825 specific 
for a Borrelia hermsii antigen (104), was added to each tube and incubated at 22°C for 
1 hr. Seventy five microliters of prewashed Pansorbin was added and the mixture was 
incubated for 10 min at 22°C. The Pansorbin was collected by centrifugation for 1 min 
at 10,000 x g. The samples were washed three times in 750 pi of NET buffer. The 
final pellet was resuspended in 50 pi o f sample buffer and boiled for 5 min. Samples 
were centrifuged at 3,000 x g to pellet insoluble material, and the supernatant was 
loaded onto 12.5% SDS-PAGE gel. Gels were electrophoresed for 3.5 hr at 250 volts
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and subsequently silver stained. Immunoprecipitation was also attempted with 
ZYMED (recombinant protein A-sepharose 4B conjugate, ZYMED Laboratories, Inc., 
San Francisco, CA), but high background and low recovery of P39 were found to occur 
with this product and therefore was not used in this study.
6. Genetic manipulation of the cloned P39 gene
To determine if P39 expression in B.burgdorferi is required for the infectivity 
of the organism, or involved in the pathology in Lyme disease an attempt was made to 
inactivate the P39 gene in the spirochete. Two strategies were employed to inactivate 
the endogenous P39 gene: first, a P39-LacZ gene fusion, and second, a P39 deletion 
mutant construct.
a. Attempts to construct a P39-LacZ fusion gene
A unique restriction site Bsu36I was detected 90 nucleotides 3’ of the start codon of 
P39 (Appendix 1). This site was selected as the insertion point for the LacZ gene.
The proximity to the start site ensures no functional P39 activity will exist in the P39 
lacZ fusion. The lacZ gene already contains a Bsu36I site at the 5’ end of the gene but 
does not contain a Bsu36I site at the 3’ end of the gene (Appendix 2). Two different 
strategies were employed for creating a 3’ sticky end compatible with the P39 Bsu36I 
site. The first approach required using oligo linkers to insert a new Bsu36I site within 
the BamHI site 3’ of LacZ gene. The second strategy utilized a Mael site (sequence 
compatible sticky end) 3’ of the LacZ gene instead of creating a new Bsu36I site.
(1). Plasmid pSPR33
The plasmid pSPR33, encoding P39, was given to this lab in a glycerol stock of 
JM109 Kcoli cells. A sample from the glycerol stock was streaked onto a LB agar 
plate containing 200 mg/ml ampicillin (LB/Amp). Plates were incubated overnight at 
37°C. One colony was selected from the plate, inoculated into 5 ml of LB/Amp media, 
and incubated overnight at 37°C with constant rotation. For large scale production of 
the plasmid, 150 ml of LB/Amp was inoculated with 1.5 ml of overnight culture, and
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incubated overnight at 37°C with constant rotation. The culture was harvested the next 
day by centrifugation at 14,000 rpm x 2 min x 4°C. Purified plasmid was collected 
from the culture using QIAGEN midi kit as directed by the manufacturer (QIAGEN 
Inc., Chatsworth, CA). The directions for the midi prep are shown below. The cell 
pellet was resuspended in 4 ml of Resuspension Buffer PI. Four ml o f Lysis Buffer 
P2 are added, mixed gently by inversion of tube, and incubated at room temp for 5 min. 
Four ml of Neutralization Buffer P3 are added and mixed immediately by inversion of 
the tube, and incubated on ice for 15 min. The samples are then centrifuged for 30 
min. at 30,000 x g at 4°C. The supernatant is removed promptly and is passed over an 
equilibrated QIAGEN column (previously washed with Equilibration Buffer QBT) 
which acts to retain the plasmids. The column is then washed twice with 10 ml of 
Wash Buffer QC. This removes all nonspecifically bound molecules from the column. 
The plasmid prep is then eluted off of the column with 5 ml of Elution Buffer QF.
The eluate, containing the plasmid prep, is collected in a clean tube. The plasmid DNA 
is then precipitated with 0.7 volumes of room temperature isopropanol, and centrifuged 
immediately at 15,000 x g at 4°C for 30 min. The supernatant is carefully removed.
The pellet, containing plasmid DNA, is washed with 5 ml of cold 70% EtOH. The 
pellet is then air dried, and resuspended in 100 ml o f sterile distilled H20  (dHOH). The 
DNA concentration is determined by absorbance at 260nm on a UV 
spectrophotometer.
(2). plasmid pCHHO
The plasmid pCHl 10 (encoding LacZ) was given to this lab as a glycerol stock. 
A sample from the glycerol stock was streaked onto a Luria broth (LB) agar plate 
containing 200 pg/ml ampicillin (LB/Amp). Plates were incubated overnight at 37°C. 
One positive colony was selected and a plasmid prep was prepared as described above.
(3). Creating new Bsu36I site 3’ of LacZ gene
Ten micrograms of pCHl 10 was digested with BamHI, and the digested DNA 
was purified on a 5% acrylamide gel, electroeluted and ethanol precipitated as
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previously described. The ends of the linearized pCHl 10 was dephosphorylated using 
calf intestinal alkaline phosphatase treatment (CIAP, Promega). The purpose of CIAP 
is to remove the phosphate group from the ends of the digested plasmid, thereby 
preventing religation o f the plasmid in the absence of an insert. The DNA was then 
purified using phenol chloroform extraction and ethanol precipitation. The 
oligonucleotides (synthesized at the Core Molecular Biology Laboratory, EVMS) 
encoding a new Bsu36I site were first annealed to each other prior to use in the ligation 
with pCHl 10. The ligation was performed at three different ratios of vector and insert 
DNA; 1:1,1:3, and 3:1. Ligation reactions were screened in JM109 E.coli Ampr.
(4). Using sequence compatible ends for insertion of LacZ into P39
Ten micrograms of unmodified pCHl 10 (Appendix 2) was digested with Bsu36I and 
Mael. The digested DNA (pCHl 10*B*M) was electrophoresed on an agarose gel.
The insert was excised from the gel and electroeluted. The insert DNA was then 
concentrated by ethanol precipitation. Ten micrograms of PSPR33 was digested with 
Bsu36I followed by CIAP. The digested DNA was purified as described above. 
Ligation of vector and insert DNA was performed at three different ratios 1:1,1:3, and 
3:1. Ligation reactions were screened in JM109 Ecoli Ampr .
b. Attempts to construct a P39 deletion mutant
A 10 pg aliquot o f pSPR33 was digested with restriction enzymes Bsu361 and 
Bal I (New England BioLabs). The digestion results in liberation of a -300 base pair 
fragment from the P39 open reading frame (approximately 300 bases 3’ of the start 
site). To this reaction was added 1.5ml of Klenow fragment (3 units Boeringer 
Manheim digitonin label kit), 2 ml of 0.5 mM dATP and 2 ml of 0.5 mM dTTP. This 
mixture was incubated at 30°C for 15 min. The mixture was then heated to 75°C for 
10 min to heat inactivate the enzymes. The DNA was purified by phenol extraction, 
followed by ethanol precipitation. The DNA pellet was resuspended in 8 ml of water 
and used in a ligation reaction with 1 ml of T4 DNA ligase, and 1 ml of 1 Ox blunt end 
buffer. The ligation reaction was incubated at 17°C for 5 hours. The ligation was
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screened in JM109 E.coli cells. E.coli cells were thawed on ice for 10 min and 40 ml 
of cells are placed in a prechilled 0.2cm electroporation cuvette. Eight microliters of 
ligation mix were added to the cuvette, and the cells were electroporated at 2.5 volts, 
200 Ohms, 25mF. One ml o f S.O.C. medium was immediately added to the cuvette, 
then transferred to a culture tube. The tube was incubated for 1 hour at 37°C with 
constant rotation. Cells (200 pi) were streaked on LB/amp plates, and incubated at 
37°C, overnight. Several colonies were selected, grown overnight in 5 ml o f LB/amp 
broth, and were screened by Pst I digestion of miniplasmid preps. Colonies containing 
the P39 deletion construct had digestion products migrating at 1.4kb, 3.5kb, and 4.5kb, 
as compared to the wild type plasmid which had digestion products migrating at 1.7kb, 
3.5kb, and 4.5kb. One positive colony (designated P39dm) was grown overnight in 
150 ml of LB/amp, and the pSPR33 deletion-mutant plasmid collected with using a 
QIAGEN prep kit as described above.
(1). Lack of P39 expression by P39 deletion mutant construct in E.coli
An aliquot of P39dm was harvested and washed three times in PBS to remove 
all traces of media The cells were adjusted to 0.20 OD at 650 nm and subsequently 
sonicated for one min on ice to break apart the cells. Two fold dilutions of P39dm 
were plated on a microtiter plate in sodium bicarbonate buffer. Controls included 
untransformed JM109 and JM109 expressing pSPR33 at the same concentration. All 
samples were tested in triplicate. Plates were incubated overnight at 4°C and screened 
by ELISA for P39 expression as described above.
c. Transformation of B.burgdorferi
The P39 deletion mutant construct was excised from the plasmid using Pst I 
digestion. The digested plasmid was ethanol precipitated overnight. The digested 
DNA was used to transform low passage infectious CN40. Spirochetes were collected 
from mid-log phase culture, washed twice with cold PBS, and then washed three times 
in cold EPS. The spirochetes were resuspended to a final concentration of 2 x 10s 
cells/ml. Fifty microliters were transferred to a prechilled 0.2 cm electroporation
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cuvette along with 2 jag P39 deletion mutant DNA. One pulse was administered at 
2.5kV, 25mF, 200 Ohms (Gene Pulser n, Bio Rad, Melville, NY) producing a time 
constant of 4-5 millisec. One ml of BSK II medium with no antibiotics was added to 
the cuvettte and transferred to 5 ml o f BSK II medium and incubated for 24 hours at 
33°C.
The electroporated spirochetes were then screened by ELISA for expression of 
flagellin (to confirm presence of spirochete) and loss of P39 expression (to confirm 
transformation of spirochete) using the following protocol. Twenty four hours after 
electroporation, the spirochetes were counted on a Petroff-Hauser chamber. The 
organisms were diluted in BSK II medium and plated out on 96 well tissue culture 
plates at approximately one spirochete per well. The plates were incubated at 33°C for 
10 days. A 50 ml aliquot was removed and saved from each well, then the original 
plates were centrifuged at 3,000 rpm for 5 min to pellet the cells. Media was removed 
from each well by aspiration. The cells were resuspended in 200 ml o f sodium 
bicarbonate buffer. The solution was divided equally between two microtiter plates 
(one hundred microliters per well) and both plates were incubated at 4°C overnight. 
The plates were rinsed 3 times with PBS, and a 1/200 dilution of Mab D1C9 (specific 
for P39) was added to one plate and a 1/100 dilution of Mab H9724 (specific for 
flagellin). The plates were incubated at room temperature for 30 min with constant 
rotation. The plates were washed 3 times with PBS, and bound antibody was detected 
with a peroxidase conjugate (goat anti-mouse IgG) at 1/2000 dilution. The plates were 
incubated at room temperature for 30 min with constant rotation. Plates were washed 3 
times with PBS, and 100 ml of peroxidase substrate (KPL) was added to each well. 
Reactivity was detected on a spectrophotometer at 650 nm.
Flagellin reactivity was used to detect the wells containing spirochetes (as 
opposed to being an empty well). P39 reactivity of each well was compared to that of 
control wells containing unelectroporated B.burgdorferi. Readings which fell below (>
0.1 OD below control well) those obtained from the untransformed spirochetes was 
considered a P3 9-low reading. This cut off level was selected in order to ensure all
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
35
possible transformants would be detected. Samples that exhibited flagellin reactivity, 
but were scored as low for P39 reactivity, were grown in culture for 10 days. These 
cultures were subsequently examined by western blot to assess P39 expression in these 
organisms.
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m . RESULTS
A. Establishment of infectious and noninfectious isolates of Borrelia burgdorferi
The infectivity of the low and high passage isolates, as defined by the ability to 
survive in a host, was assessed in mice by needle inoculation. It was important to 
confirm the infectivity status o f these isolates since the remainder of the study involves 
comparison of the infectious and noninfectious isolates. Accordingly, three separate 
methods were used for verifying isolate infectivity: culture of mouse tissue, 
xenodiagnosis using ticks, and finally PCR of mouse tissue. Low passage CN40 p9,
B31 p6, WCHI p6 and JD1 p3 and high passage CN40 p22 were all infectious based 
on recovery of spirochetes from mouse bladder tissue (Table 1). In contrast, the high 
passage isolates B31 p.32, WCHI p. 15, and JD1 p. 15 were not recovered from mouse 
tissue.
In addition, Borrelia were detected in ticks which fed on mice infected with 
low passage WCHI and JD1 respectively (Table 1). No Borrelia were detected in ticks 
which fed on mice inoculated with high passage WCHI and JD1.
The tissues from infected mice (inoculated with low passage B31, WCHI, JD1, 
low and high passage CN40) were also positive for B.burgdorferi infection when 
assayed by PCR using primers specific for B.burgdorferi chromosomal DNA (Fig. 1). 
Tissues from noninfected mice (inoculated with high passage B31, WCHI, and JD1) 
were not positive by PCR. Borrelia burgdorferi DNA was detected at a sensitivity of 
10 pg of spirochetal DNA (control lanes panel A, lane 9-12).
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Table 1. Infectivity of low and high passage Borrelia burgdorferi isolates.
Isolate Passage Tissue* Tick” PCR6 Infectivity0
CN40 9 2/2 nd 2/2 I
CN40 22 2/2 nd nd I
B31 6 2/2 nd 2/2 I
B31 32 0/4 nd 0/4 N
WCHI 6 2/2 1/14 2/2 I
WCHI 15 0/4 0/12 0/4 N
JD1 3 2/2 3/20 2/2 I
JD1 15 0/4 0/14 0/4 N
* Recovery of B.burgdorferi from cultured bladder tissues. Total number 
positive/total number tested. All negative cultures were confirmed by repeating 
the experiment.
b IFA detection of B.burgdorferi in ticks which had fed on inoculated mice. Total 
number of positive ticks/total number of ticks tested. nd=experiment not done. 
c Detection of B.burgdorferi DNA in mouse bladder tissue by PCR. 
dInfectivity of B. burgdorferi isolate I=infectious, N=noninfectious.
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Figure 1. Detection of Borrelia burgdorferi DNA in mouse bladder tissue 
using PCR. Template DNA was collected from mice inoculated with the 
following low or high passage isolates: CN40 p.9 (panel A, lane 1 and 2), B31 
p.6 (panel A, lane 3 and 4), B31 p.32 (panel A, lanes 5-8), WCHI p.6 (panel 
B, lane 1 and 2), WCHI p. 15 (panel B, lanes 3-6), JD1 p.3 (panel B, lane 7 
and 8), JD1 p. 15 (panel B, lanes 9-12). DNA size markers are shown in lane 
13 of panel A and B. Control for PCR sensitivity shown in panel A: 500ng 
of DNA extracted from uninfected mouse tissue was mixed with lug (lane 9), 
lOng (lane 10), or 10 pg (lane 11) o f template B.burgdorferi DNA to 
determine interference with PCR. A negative control is shown in A, lane 12.
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Based on these three separate criteria (tissue culture, xenodiagnosis, and PCR) 
low passage CN40, B31, WCH1, JD1, and high passage CN40 were judged to be 
infectious and high passage B31, WCH1, and JD1 were noninfectious. These 
infectious and noninfectious organisms were next analyzed for P39, OspB, OspA, and 
Fla localization within the spirochetal cell to determine if a correlation exists between 
P39 localization and infectivity.
B. Subcellular localization and quantitation of P39, OspB, OspA, and Fla in 
infectious and noninfectious isolates
1. Western blot of cell fractions
Infectious and noninfectious B.bvrgdorferi were separated into outer envelope, 
inner membrane, and cytosolic fractions and analyzed by western blot /densitometry to 
quantitate the antibody reactivity for each epitope (hereafter referred to as levels). The 
P39, OspB, and OspA levels for infectious and noninfectious isolates were analyzed by 
regression analysis to determine the statistical significance.
a. P39 levels
For all isolates, a decrease in P39 levels in the outer envelope correlated with 
loss of infectivity {P = 0.019) (Table 2). However, no significant interaction exists 
between the amount of P39 in the inner membrane (P = 0.24) or cytosolic fraction and 
infectivity (P = 0.32).
There was considerable variability in P39 localization among isolates. Most 
notably the P39 levels in the cloned, infectious isolate CN40 was located exclusively in 
the outer envelope fraction. No P39 was detected in the inner membrane or cytosolic 
fractions (Table 2, Fig. 2). Both outer envelope fractions of CN40 had comparable P39 
levels, therefore P39 expression did not increase or decrease during in vitro culture.
In contrast, the P39 levels in the remaining uncloned isolates did change. For 
B31, P39 was detected in all cell fractions, except infectious cytosol (Table 2, Fig. 3).
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Table 2. P39 levels in Borrelia burgdorferi cell fractions measured by 
westernblot densitometry. ‘
Isolate Infectivity OE IM CY Cumulative
CN40 (p5) I 0.639 ±0.10 0 0 0.639
CN40 (p23) I 0.727 ±0.11 0 0 0.727
B31 I 0.187 ±0.11 0.124 ±0.10 0 0.311
B31 N 0.467 ±0.14 0.171 ±0.07 1.09 ± 0.17 1.728
WCH1 I 1.534 ±0.28 1.076 ±0.22 0.177 ±0.11 2.787
WCH1 N 0.883 ±0.15 1.254 ±0.25 0.235 ± 0.15 2.372
JD1 I 1.154 ±0.14 1.213 ±0.18 0.459 ± 0.12 2.826
JD1 N 0.713 ± 0.13 1.406 ±0.22 0.654 ± 0.08 2.773
Mean I 0.847 0.603 0.159 1.573
N 0.687 0.708 0.495 1.901
*Data shown represent the mean of four independent experiments ± SEM.
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Figure 2. Detection of P39, OspB, and OspA in infectious CN40 cell fractions at
p5 and p23 by westernblot. Eight microliters o f whole cell sonicate (WC), 
protoplasmic cylinder (PC), outer envelope (OE), cytosolic (CY), or inner membrane 
(IM) fraction were analyzed.
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Figure 3. Detection of P39, OspB, and OspA in low and high passage B31 cell 
fractions by western blot. A total of eight microliters of outer envelope (OE), 
cytosolic (CY), or inner membrane (IM) fractions were analyzed.
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Figure 4. Detection of P39, OspB, and OspA in low and high passage WCH1 cell 
fractions by western blot. Eight microliters of cytosolic (CY), inner membrane 
(IM), and outer envelope (OE) fractions were analyzed. Flagellin control is marked 
(>) in IM fraction.
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Figure 5. Detection of Fla, P39, OspB, and OspA in low and high passage JD1 
cell fractions by western blot. Eight microliters of outer envelope (OE), cytosolic 
(CY), or inner membrane (IM) fractions were analyzed.
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Table 3. OspB levels in Borrelia burgdorferi cell fractions measured by
western blot densitometry.*
Isolate Infectivity OE IM CY Cumulative
CN40 (p5) I 0.863 ± 0.20 0.181 ±0.11 0 1.044
CN40 (p23) I 0.988 ± 0.30 0.098 + 0.15 0 1.086
B31 I 0.426 ±0.20 0.850 ±0.20 0.286 ±0.14 1.562
B31 N 1.16 ±0.22 1.99 ±0.31 1.8 ±0.45 4.950
WCH1 I 1.793 ±0.32 1.796 ±0.42 0.298 ±0.10 3.887
WCH1 N 1.246 ±0.27 1.834 ±0.48 0.248 ±0.04 3.328
JD1 I 0.954 ±0.34 1.350 ±0.41 0.426 ±0.17 3.684
JD1 N 0.481 ± 0.20 1.520 ±0.49 0.323 ±0.15 2.324
Mean I 1.009 1.044 0.252 2.544
Mean N 0.968 1.360 0.592 2.922
*Data shown represent the mean of four independent experiments ± SEM.
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Table 4. OspA levels in Borrelia burgdorferi cell fractions measured by western
blot densitometry.*
Isolate Infectivity OE IM CY Cumulative
CN40 (p5) I 0.922 ±0.20 0.732 ±0.30 0 1.654
CN40 (p23) I 0.994 ±0.20 0.435 ±0.40 0 1.429
B31 I 0.555 ±0.20 1.138 ±0.22 0.413 ±0.21 2.106
B31 N 1.05 ± 0.70 1.93 ±0.40 1.25 ±0.32 4.230
WCH1 I 1.781 ±0.18 2.079 ±0.17 0.742 ±0.18 4.602
WCH1 N 1.825 ±0.12 2.008 ± 0.25 0.675 ±0.18 4.508
JD1 I 1.238 ±0.50 2.590 ±0.61 1.120 ±0.37 4.948
JD1 N 1.150 ±0.40 2.240 ±0.43 1.090 ±0.38 4.480
Mean I 1.124 1.634 0.568 3.327
Mean N 1.254 1.653 0.753 3.661
*Data shown represent the mean of four independent experiments.
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Table 5. Flagellin levels in Borrelia burgdorferi cell fractions measured by
westernblot densitometry.*
Isolate Infectivity OE IM CY Cumulative
CN40 (p5) I 0 ndb nd nd
CN40 (p23) I 0 nd nd nd
B31 I 0 nd nd nd
B31 N 0 nd nd nd
WCH1 I 0 0.426 0.030 0.456
WCH1 N 0 0.611 0.050 0.661
JD1 I 0 0.734° 0.155 0.889
JD1 N 0 0.909d 0.045 0.954
Mean I 0 0.58 0.092 0.672
Mean N 0 0.76 0.047 0.807
“Data shown represent the mean of four independent experiments. SEM < 
0.05 unless otherwise indicated. 
bnd = not determined.
CSEM = 0.2 
dSEM = 0.1
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In infectious B31 cell fractions, the P39 was located in the membrane fractions only. 
However, noninfectious fractions had considerably more P39 and the majority was in 
the cytosolic fraction. For the other uncloned isolates WCH1 and JD1, P39 was 
detected in all fractions (Fig. 4 and 5). However, decrease in P39 was detected in the 
noninfectious outer envelope fraction of WCH1 and JD1 (Table 2). This decrease 
corresponds with a slight increase in noninfectious inner membrane fractions, and 
cytosolic fraction for both isolates.
b. OspB levels
No significant interaction exists between infectivity and OspB localization in 
any cell fraction: outer envelope (P = 0.65) inner membrane (P = 0.20), cytosol (P =
0.65). For the infectious CN40, OspB levels were observed in both the outer envelope 
and inner membrane fractions but were not seen in the cytosolic fractions (Table 3, Fig. 
2). Notably, the OspB levels for CN40 did not change from low to high passage. In 
contrast, OspB (Table 3, Fig.3) was detected in all fractions o f B31, but noninfectious 
cell fractions contained twice the amount of OspB. OspB was also detected in all 
fractions o f WCH1 and JD1 (Table 3). The amount of OspB in the outer envelope 
fraction decreased in both noninfectious WCH1 and JD1, but inner membrane and 
cytosolic levels remained the same.
c. OspA levels
No significant interaction exists between infectivity and OspA localization in any cell 
fraction: outer envelope (P = 0.15), inner membrane (P = 0.27), cytosol (P = 0.19).
For CN40, OspA was detected in both the outer envelope and inner membrane 
fractions but were not seen in the cytosolic fractions (Fig. 2, Table 4). CN40 OspA 
levels did not change with in vitro culture, this is consistent with CN40 P39 and OspB 
levels. In contrast, OspA was detected in all fractions of B31, but noninfectious cell 
fractions contained twice the amount of OspA (Fig.3, Table 4). OspA was also 
detected in all cell fractions of WCH1 and JD1 (Table 4). OspA was equally 
distributed between the membrane fractions of WCH1, and did not change with
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infectivity. For JD1, the majority of OspA was located in the inner membrane fraction, 
and this did not change with infectivity. For all isolates there was no significant 
correlation between OspA localization and infectivity.
d. Flagellin levels
Flagellin levels were monitored simply as a quality control measure for the cell 
fractionation procedure. No flagellin was detected in any outer envelope fraction, 
indicating proper fractionation of the isolates (Table 5). Flagellin was detected in the 
inner membrane fraction and trace amounts in the cytosol. Noninfectious and 
infectious isolates had similar flagellin levels in the inner membrane fraction.
2. Quality control measures for fractionation technique and densitometry 
analysis
a. Interassay variation of cell fractionation
The reproducibility of the fractionation procedure was monitored by protein 
assay. The protein distribution within spirochete cell fractions was as follows: 90-93% 
in the outer envelope, 4-8% in the inner membrane, and 0.6-1.8% in the cytosolic 
fraction. The average amount of protein from 1 xlO6 infectious spirochetes was 2.0 mg 
(93% of total) in the outer envelope, 0.1 mg (4.6% o f total) in the inner membrane, and
0.04 mg (1.8% of total) in the cytosolic fraction. When the protein concentrations of 
the cell fractions were added together in all cases the total was equal to (100%) or 
slightly higher than (101-107%) the protein concentration for the whole cell sonicate 
preparation. For noninfectious organisms, there was nearly twice as much protein 
from the same number o f spirochetes: 4.0 mg in the outer envelope, 0.2 mg in the 
inner membrane and 0.07 mg in the cytosolic fraction. The protein concentration of 
cell fractions generated from duplicate samples of CN40 (two populations o f CN40 
subjected to cell fractionation on different occasions) were analyzed by students T test. 
No significant differences exist between protein concentrations of cell fractions from 
duplicate samples (P =0 .3736).
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b. Localization of cell fraction markers
The flagellin protein is the major component o f the spirochete flagella. 
Physiologically it is anchored to the inner membrane. When the cell is fractioned, the 
flagellin should partition with the inner membrane fraction. Any detection o f flagellin 
in the outer envelope fraction would be evidence of improper separation of the 
fractions. There was no control for outer membrane contamination of the inner 
membrane or cytosolic fractions as no outer envelope specific marker had been 
identified for B.burgdorferi. For all isolates analyzed, no flagellin was detected in the 
outer envelope fraction indicating proper fractionation of the cell (Table 5). Flagellin 
was detected primarily in the inner membrane fraction, and trace amounts (0-2%) were 
detected in the cytoplasmic fraction of WCH1 and JD1.
c. Western blot/densitometry assessment
To ensure proper detection of bands by the densitometer, the densitometer sensitivity 
was assessed. Duplicate serial dilutions o f whole cell B.burgdorferi antigen (Oug- 
30ug) were subjected to SDS-PAGE and western blot (purified P39, OspB, or OspA 
were not used for assessment o f the densitometer since cell fractions, not purified 
proteins, are the subject of this study). The blot was treated with monoclonal 
antibodies specific for P39, OspA, and OspB and developed as described above. A 
linear relationship was demonstrated between densitometer absorbance readings and 
serial dilutions of whole cell B.burgdorferi antigen less than 30 ug (P39 Y = 0.04X +
0.628; OspB y = 0.037X + 0.167; OspA Y = 0.0368X + 0.3568) (Appendix 3). 
Therefore, the densitometer was able to quantitate P39, OspA, and OspB in antigen 
samples less than 30ug. The protein concentration in 8ul of each cell fraction (2.8 x 10s 
spirochetes, the amount used in the SDS-PAGE in this study) is less than 15 ug. All 
fractions from one isolate (both low and high passage) were analyzed on the same blot, 
thereby minimizing differences in development. A minimum of three experiments 
were performed with each isolate, and densitometry readings were analyzed by linear 
regression analysis to determine the statistical significance.
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3. Silver stain analysis of cell fractions
Cell fractions o f the infectious and noninfectious spirochetes were also 
analyzed by SDS-PAGE and silver stain to detect any other changes in protein 
expression which might correlate with loss of infectivity. All isolates (infectious and 
noninfectious) had bands migrating at 14,20,22 (corresponding to OspC), 29,32 
(corresponding to OspA), 34 (corresponding to- OspB), and a large band at 50-66 kD in 
the whole cell sonicate (Figs.6-9).
a. Outer envelope fraction
For all isolates, the majority of detectable proteins were in the outer envelope 
fraction. Most bands detected in the whole cell sonicate were also detected in the 
outer envelope. For the infectious isolate CN40, all corresponding bands in low and 
high passage fractions appeared to stain with equal intensity (Fig. 6). For isolate 
B31, infectious and noninfectious outer envelope fractions displayed different 
staining intensities for many bands; most notably bands o f 24,22 and 20 kD were all 
detectable in the infectious outer envelope fraction yet absent from the noninfectious 
fraction (Fig. 7). WCH1 also exhibited several differences between infectious and 
noninfectious outer envelope fractions (Fig. 8). Infectious outer envelope had 
distinct bands migrating at 36 and 39 kD. In the noninfectious fraction the 36 kD 
band was greatly diminished and the 39 kD band was completely absent. All other 
corresponding bands in WCH1 outer envelope fractions appeared to have equal 
intensity. JD1 also exhibited changes in band intensities between infectious and 
noninfectious outer envelope fractions (Fig. 9). The noninfectious outer envelope 
fraction contained darker bands migrating at 47,45,34, 32, and 14 kD, but a lighter 
band at 29 kD as compared to the corresponding infectious fraction.
b. Innermembrane fraction
For all isolates very few bands were detected in the inner membrane fraction. 
All isolates (except JD1) had a 66 kD band. CN40 also had a band at 20 kD in the high 
passage fraction. For B31, faint bands at 41, 33, and 21 kD could be seen in the
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Figure 6. Silver stain analysis of infectious isolate CN40 cell fractions.
Eight microliters of the cell fractions are represented in each lane. Whole 
cell sonicate (WC), outer envelope (OE), inner membrane (IM) and cytosolic 
(CY) fractions are shown. Molecular weight markers are indicated to the left 
o f the gel.
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Figure 7. Silver stain analysis of B31 cell fractions. Eight microliters of 
cell fractions were electrophoresed on a 12.5% gel and silver stained to detect 
proteins. Whole cell sonicate (WC), outer envelope (OE), inner membrane 
(IM) and cytosolic (CY) fractions from infectious (I) and noninfectious (N) 
B31 are shown. Molecular weight markers are indicated to the left o f the gel.
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Figure 8. Silver stain analysis of WCH1 cell fractions. Eight microliters of 
cell fractions were electrophoresed on a 12.5% gel and silver stained to detect 
proteins. Whole cell sonicate (WC), outer envelope (OE), inner membrane 
(IM) and cytosolic (CY) fractions from infectious (I) and noninfectious (N) 
WCH1 are shown. Molecular weight markers are indicated to the left of the 
gel.
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Figure 9. Silver stain analysis of JD1 cell fractions. Eight microliters of 
cell fractions were electrophoresed on a 12.5% gel and silver stained to detect 
proteins. Whole cell sonicate (WC), outer envelope (OE), inner membrane 
(IM) and cytosolic (CY) fractions of infectious (I) and noninfectious (N) JD1 
are shown. Molecular weight markers are indicated to the left of the gel.
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noninfectious inner membrane fraction, but were not seen in the infectious inner 
membrane fraction. For WCH1, bands migrating at 29,41, and 60 kD were detected 
in both inner membrane fractions but appeared to be darker in the noninfectious 
fraction. Additional bands at 52,54, and 60 kD were also evident in the noninfectious 
inner membrane fraction. For JD1 both inner membrane fractions had bands of equal 
intensity migrating at 29,31, and 41 kD.
c. Cytosolic fraction
All isolates displayed a single large band at 66 kD for both cytosolic fractions. 
For CN40 this was the only band detected. A distinct band in the cytosolic fraction of 
infectious B31 migrated at 66 kD, while the noninfectious cytosolic fraction contained 
several additional faint bands at 60,40,34,33,22, and 18 kD. A single band of 66 kD 
was detected in both cytosolic fractions of WCH1, although it appeared to be more 
intense in the noninfectious passage. Additionally, both cytosolic fractions from JD1 
contained a single band migrating at 66 kD, but the band in the noninfectious fraction 
was considerably darker. Proteins are present in the inner membrane and cytosolic 
fractions as evidenced by BCA protein assay; however, not all proteins are detected by 
silver staining, and the intensity of staining depends upon the individual characteristics 
of each protein.
These data demonstrate several differences in protein expression between 
infectious organisms and noninfectious organisms. CN40 alone remains unchanged in 
low and high passage. B31 had two bands in the outer envelope fractions with 
different intensities (29 kD and 20 kD), and the noninfectious inner membrane and 
cytosolic fractions both contained bands which were not found in the corresponding 
infectious fractions. WCH1 noninfectious outer envelope fraction lacked two bands 
(36 kD and 39 kD) found in infectious fraction, and overall noninfectious fraction 
bands were darker in both inner membrane and cytosolic fractions. JD1 had disparity 
in band intensities between infectious and noninfectious cell fractions, but the loss or 
gain of bands was not noted. The fact that B31, WCH1, and JD1 are uncloned
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populations of spirochetes may account for the differences seen between low and high 
passage organisms.
C. Surface expression of P39, OspB, and OspA as detected by flow cytometry
The uniformity o f P39, OspB, or OspA surface expression in a population of 
spirochetes was assessed by flow cytometry. Distinct peaks show uniformity of 
expression in a population. Flat or broad peaks are a sign of variability in surface 
expression among the population of spirochetes.
1. Differences in levels of P39 expression in clones derived from parental isolate 
WCH1
Clones of isolate WCH1 were generated for this study in order to compare P39 
surface expression o f clones to the original uncloned population of spirochetes.
Parental, uncloned WCH1 and WCH1 clones were first analyzed by ELISA for P39 
expression. A single clone, Clone 1, showed marked differences in P39 reactivity as 
compared to uncloned WCH1. Clone 1 had higher P39 reactivity in whole cell antigen 
preparations than uncloned WCH1 (O.D. values at 260 nm were 0.62 versus 0.38 
respectively). All other clones had P39 reactivity similar to uncloned WCH1. Due to 
the differences in P39 reactivity, Clone 1 was selected for further study by flow 
cytometry.
2. P39 surface expression
In order to determine the variability o f P39 surface expression in cloned and 
uncloned isolates, low and high passage whole cell B31, WCH1, JD1, WCH1 clone 1, 
and high passage CN40 were analyzed by flow cytometry. The infectious, cloned 
isolate CN40 had a single, very low intensity peak for P39 indicating the cloned 
spirochetes’ uniform reactivity to Mab D1C9 (mean fluorescence = 72.9, Table 6,
Fig. 10). A single peak was also observed in both low and high passage WCH1 clone 1, 
and had a mean fluorescence of 111.5 for p7 and a mean of 104.0 for p 17. The P39 
reactivity was not uniform in the uncloned isolates B31, WCH1, and JD1. Infectious
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Table 6. Surface expression of P39, OspB, and OspA as detected by flow 
cytometry.
Isolate Infectivity P39 OspB OspA
CN40 p22 I 72.9 ±31.4 165.6 ±35.7 120.7 ±45.3
clone I p7 ndb 111.5 ±29.1 100.7 ±30.4 59.2 ±26.8
clone I pl7 nd 104.0 ±35.4 136.0 ±36.1 50.4 ± 23.8
B31 I 140.8 ±44.0 nd nd
B31 N 84.7 ±34.1 103.4 ±26.5 41.6 ± 22.8
WCH1 I 130.8 ±51.3 135.4 ±33.4 54.7 ± 25.8
WCH1 N 107.4 ±38.3 143.4 ±32.7 73.2 ±30.0
JD1 I 136.6 ± 51.3 126.9 ±33.5 51.2 ±24.3
JD1 N 88.3 ±33.8 116.2 ±32.0 66.8 ± 26.2
a Mean fluorescence ± standard error are shown. 
b nd= not determined.















Figure 10. P39 surface expression as detected by flow cytometry. Infectious (I) and 
noninfectious (N) spirochetes were incubated with monoclonal D1C9, followed by a 
fluoroscein labeled secondary antibody, and assessed by flow cytometry. Panel A isolate 
CN40, panel B WCH1 clone 1 p7 and p 17 (infectivity unknown), panel C isolate B31, 
panel D isolate WCH1, and panel E isolate JD1.
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Figure 11. OspB surface expression as detected by flow cytometry. Infectious (I) and 
noninfectious (N) spirochetes were incubated with monoclonal H6831, followed by a 
fluoroscein labeled secondary antibody and assessed by flow cytometry. Panel A isolate 
CN40, panel B WCH1 clone 1 p7 and p l7  (infectivity unknown), panel C isolate WCH1 
and panel Disolate JD 1.
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Figure 12. OspA surface expression as detected by flow cytometry. Infectious (I) and 
noninfectious (N) spirochetes were incubated with monoclonal antibody H5332, 
followed by a fluoroscein labeled secondary antibody and assessed by flow cytometry. 
Panel A isolate CN40, panel B WCH1 clone 1 p7 and p 17 (infectivity unknown), panel 
C isolate B31, panel D isolate WCH1, and panel E isolate JD 1.
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B31, JD1, and WCH1 all displayed skewed peaks. In addition, all uncloned isolates 
exhibited higher P39 surface expression in the infectious population than the respective 
noninfectious population. The nonifectious samples’ peaks remained skewed but there 
was a noticeable overall decrease in P39 reactivity. These data demonstrate the shift in 
outer surface P39 expression in uncloned organisms upon in vitro cultivation. This 
change may be due to a selection during in vitro culture of a particular subpopulation of 
spirochetes, or a change in the expression of the protein within the whole population of 
spirochetes.
3. OspB surface expression
All isolates had very distinct peaks for OspB (Fig. 11). Clone 1 increased from a 
mean fluorescence of 100 to a mean of 136 from p7 to p i7, but all other isolates 
remained relatively unchanged (Table 6). Overall OspB expression appeared 
uniform throughout cloned and uncloned populations, and did not change in intensity 
from low to high passage.
4. OspA surface expression
CN40 displayed two distinct peaks for OspA reactivity demonstrating two 
subpopulations varying in OspA expression (Fig. 12). Either there are two 
subpopulations within this cloned population of spirochetes, or the spirochetes are 
differentially regulating the OspA expression. All other isolates, cloned and 
uncloned, had single distinct peaks for OspA expression indicating uniform surface 
expression of this molecule.
D. Characterization of P39
1. Solubility of P39 as determined by detergent extraction
In the cell fractionation experiment, P39 was detected in membrane fractions 
as well as cytosolic fractions. Therefore the question of the solubility of P39 was 
raised. Is P39 localizing to the cytosolic fractions because of a change in the solubility 
of the molecule? B31 was the isolate with the most dramatic shift in P39 localization
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in infections and noninfectious populations (from membrane to cytosol, Table 2) and 
was therefore selected for further study. For comparison CN40 was selected because it 
retains infectivity and does not exhibit a change in P39 localization. Based on these 
criteria, the localization of P39 within the isolates B31 and CN40 was determined 
utilizing detergent solublization of whole cell sonicates, outer envelope, inner 
membrane, and cytosolic cell fractions.
P39 consistently localized to the Triton X I14 soluble fraction indicating the 
hydrophobic nature of the molecule. For CN40, P39 was detected in the Triton X I14 
soluble phase of the outer envelope fraction (Fig. 13). For B31, P39 was detected in 
the Triton X I14 soluble phase of whole cell sonicate and all three subcellular fractions 
(Fig. 14). This pattern of P39 localization in CN40 and B31 was also seen in the 
western blot analysis (Fig. 2 and 3). The consistent partitioning to the Triton X I14 
fraction indicates P39 is hydrophobic in nature and does not exhibit any change in 
solubility in infectious or noninfectious spirochetes or in different cell fractions. 
Therefore, the reason for the change of P39 localization in infectious and noninfectious 
B31 is not due to a change in the solubility o f the P39 molecule.
2. Proteins associated with P39
If the change in P39 localization in infectious and noninfectious isolates is not 
due to a change in the solubility of the P39 molecule, perhaps it is due to the molecules 
with which P39 associates. This was investigated by immunoprecipitating P39 (using 
Mab D1C9) from whole cell sonicates of CN40, B31, WCH1, and JDl and identifying 
any coprecipitating molecules. Using Pansorbin for the affinity purification of these 
complexes, a band corresponding to P39 was detected in all isolates. Figure 15 shows 
the results o f immunoprecipitation from whole cell sonicates. Controls include the 
following: whole cell antigen immunoprecipitated in the absence of D1C9 (Ag); D1C9 
immunoprecipitated in the absence of antigen (Mab); and Pansorbin with no antigen or 
antibody (Pan). Bands seen in the control lanes (designated nonspecific bands) include 
a 65, 54,52,41,36,26, and 16 kD bands. These bands appeared in the 
immunoprecipitations from the isolates and will not be discussed further. P39 was
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Fig. 13 Western blot detection o f P39 in detergent extracted cell 
fractions of infectious CN40. Triton X I14 was used to separate 
hydrophobic and hydrophilic molecules in cell fractions o f isolate 
CN40. Detergent soluble (dt) and aqueous (aq) phases of CN40 
protoplasmic cylandar (PC), and outer envelope (OE) fractions from 
p5 and p23are shown.
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Figure 14. Western blot detection of P39 in detergent extracted cell 
fractions of noninfectious B31. Triton X I14 was used to separate 
hydrophobic and hydrophilic molecules in cell fractions o f isolate B31. 
Detergent soluble (dt) and aqueous (aq) phases of high passage B31 whole cell 
(WC), cytosolic (CY), inner membrane (IM), and outer envelope (OE) fractions 
are shown.
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Figure 15. Immunoprecipitation of P39 from high passage whole cell sonicate 
of infectious isolate CN40 and noninfectious isolates B31, WCH1, and JD1.
Controls include B31 sonicate (Ag), Monoclonal D1C9 (Mab), and Pansorbin cells 
(Pan). P39 was detected in all isolates (P39). Coprecipitating molecules found only 
in B31, WCH1 and JD 1 are indicated with an arrow (>). Molecular weight markers, 
in kilodaltons, are indicated at left.
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detected in all isolates. Bands common to all four isolates include 50,39, 15, and 13 
kD. Six additional bands found in all three noninfectious isolates, but not in the 
infectious isolate CN40 include 60,46,38,32,22, and 21 kD. In addition, there were a 
29 kD and 9 kD band detected only in B31.
E. Attempts to genetically mutate the cloned P39 gene
1. P39-LacZ fusion
The first attempt to knock out P39 in B.burgdorferi was based on creating a 
P39-LacZ fusion gene. However, no successful ligations of P39 and LacZ DNA were 
detected in E.coli. Twenty five different reactions were attempted, utilizing enzymes 
and buffers from different manufacturers in an attempt to optimize the reaction. No 
successful P39-LacZ fusion gene was obtained. Therefore, instead of mutating the 
gene by insertion o f a selectable marker, the P39 gene was mutated by deletion.
2. P39 deletion-mutant
Deletion of a 300 bp fragment from the cloned P39 gene and religation to yield 
a product which was out of frame and no longer expressed P39 was successful on the 
first attempt. The P39 deletion mutant construct did not express a protein recognized 
by the Mab D1C9 as demonstrated by ELISA. The absorbance for the wild type P39 
(E.coli expressing cloned P39 gene) at 260 nm was 2.30 O.D., whereas the absorbance 
for the P39 deletion mutant (E.coli expressing mutant construct) was 1.40 O.D, and the 
negative control (E.coli with control vector) was 1.47 O.D.. In addition to providing a 
deletion-mutant construct for use in transforming B.burgdorferi, this experiment 
confirmed that the epitope for D1C9 is not contained within the first 100 amino acids 
(300 nucleotides) o f P39.
3. Screening for transformed B.burgdorferi
CN40 was the isolate selected for use in this experiment because it does not 
lose infectivity during in vitro culture. CN40 was electroporated with the linearized 
P39 deletion mutant gene. Electroporated spirochetes were assayed by ELISA for
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expression of flagellin and P39. Out o f2430 organisms 18 were concurrently positive 
for flagellin expression and low for P39 expression (as compared to untransformed 
organisms.) The qualification for a spirochete being P39 “low” was 0.1 O.D. units 
below the untransformed control spirochetes. This generous cut off point will 
invariably include P39 expressing spirochetes since this value is within the standard 
error o f the mean (0.2). The purpose was to ensure no transformants were excluded, 
even if  this meant including several nontransformed spirochetes. The 18 putative 
transformants were grown in culture for two weeks to increase the number of 
organisms. The spirochetes were subsequently-harvested from culture and assayed by 
western blot to assess the P39 expression. However, all spirochetes expressed P39 as 
detected by western blot. Therefore, no B.burgdorferi P39 deletion mutants were 
obtained, and the question of P39’s role in infectivity o f B.burgdorferi, and its role in 
the pathology of Lyme disease could not be directly addressed.
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IV. CONCLUSIONS
The purpose of this study was to biochemically characterize the P39 molecule 
and determine if a correlation exists between P39 expression and infectivity of Borrelia 
burgdorferi. The first aim was to determine where P39 is located within the spirochete, 
and determine if  localization of P39 correlates with infectivity. This comparative 
analysis necessitated the establishment of infectious and noninfectious isolates of 
B.burgdorferi.
Four different isolates were used in this study, and three separate methods were 
used for verifying isolate infectivity: culture of mouse tissue, xenodiagnosis using 
ticks, and PCR of mouse tissue. The first isolate CN40, which is the only isolate 
known to retain infectivity during prolonged in vitro culture, was shown to be 
infectious at passage 9 and passage 22 by tissue culture. The remaining isolates B31, 
WCH1, and JD1 (all uncloned organisms) were infectious at or below passage 6. Each 
isolate was recovered from the tissues of inoculated mice demonstrating persistence of 
spirochetes in tissues of the host. Transmission of spirochetes from infected mice to 
ticks, an important part of maintaining the B.burgdorferi population in the wild, was 
also demonstrated for isolates WCH1 and JD1. Other investigators report the 
transmission rate of WCH1 or JD1 from experimentally infected mice to feeding ticks 
is 1-10% (personal communication). Thus the transmission rate in this experiment, 
4.3% for WCH1 and 15% for JD1, is consistent with similar findings made elsewhere.
When B31, WCH1, and JD1 were passed 15 or more times they were not 
recovered from the tissues of inoculated mice and were not transmitted to ticks. To 
ensure that the high passage isolates were not simply more difficult to isolate from 
tissue, PCR was performed on mouse tissues. No B.burgdorferi DNA was detected at 
a sensitivity of 10 pg of spirochete DNA/500 pg mouse DNA, confirming the lack of 
infectivity of these high passage isolates. These infectious and noninfectious
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spirochetes were next analyzed for P39 localization to determine if  a correlation exists 
between P39 localization and infectivity.
As shown in the western blot/densitometry analysis o f cell fractions, there was 
a statistically significant interaction between P39 localization (outer envelope fraction 
only) and the infectivity of B.burgdorferi. High levels of P39 in the outer envelope 
correlated with infectivity of the spirochete. A decrease in P39 levels in the outer 
envelope correlated with a loss o f infectivity. No significant interaction with 
infectivity was detected for P3 9 in the remaining cell fractions, nor for OspB or OspA 
in any cell fraction. This supports the hypothesis that P39 localization is related to the 
infectivity of B.burgdorferi.
Interestingly, the cloned infectious isolate CN40 localized P39 exclusively to the outer 
envelope. Continuous culture of CN40 did not affect the localization of P39 nor the 
quantity produced. In contrast, P39 was localized to all three cell fractions of uncloned 
isolates WCH1, JD1, and B31 and continuous culture did affect the localization of P39 
in these three isolates. Noninfectious WCH1 and JD1 had far less P39 in the outer 
envelope and more P39 in the inner membrane and cytosol, whereas noninfectious B31 
had a dramatic increase of P39 in the cytosol. This shift in P39 localization was also 
demonstrated in the flow cytometry analysis; noninfectious B31, WCH1, and JD1 had 
uniformly decreased surface expression of P39 as compared to the corresponding 
infectious isolates. The changes noted in P39 localization in noninfectious B31, 
WCH1, and JD1 may have been due to clonal expansion of a particular subgroup of 
spirochetes in the uncloned population, or a widespread phenotypic change by the 
whole population of spirochetes. The cell fractionation/western blot procedure does 
not allow for differentiation between the two possibilities.
Other changes were detected in these three uncloned isolates as shown by silver 
staining. In comparison of infectious and noninfectious outer envelope, each uncloned 
isolate had at least two bands which differed in intensity: B31 had bands at 24,22 and 
20 kD; WCH1 had bands at 39 and 36 kD; JD1 had bands at 47,45,34,32,29, and 14 
kD. The cloned, infectious isolate CN40 exhibited no detectable changes in banding 
patterns in low and high passage cell fractions. For all isolates the majority of proteins
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detected by silver stain were located in the outer envelope fraction. Few proteins were 
detected in the inner membrane and cytosolic fractions even though proteins were 
present in those fractions as evidenced by western blot.
Previous studies have compared infectious and noninfectious isolates by SDS- 
PAGE silver stain and western blot (65,68,73,75,103). All o f these studies have 
used whole cell organisms and have not analyzed possible differences in protein 
localization within the spirochetal cell. Subtle changes in protein localization, such as 
those described in this study, would be easily overlooked by simple total protein 
analysis. Some previously documented changes of B31 as a result of in vitro culture 
are as follows; decrease in 24 and 20 kD molecules (also documented in the present 
study) and loss o f 35 and 28 kD molecules (75), and in another study using B31 
documented the loss o f28,26, 18 and 16 kD proteins (117).
Other investigators have selectively studied the outer envelope o f the B. 
burgdorferi in hopes of identifying virulence factors, and have separated the 
spirochetal cell using isopicnic centrifugation after disruption of the cell in a French 
pressure cell (133). However this allows mixing of the different cell fractions prior to 
separation of the fractions. This process may artificially allow proteins to separate into 
fractions in which they were not originally located. In order to avoid this dilemma in 
the present study the outer envelope was first removed from the protoplasmic cylinder 
using a mild detergent solution. This outer envelope fraction was then separated from 
the protoplasmic cylinder by centrifugation. The protoplasmic cylinder was then 
sonicated to break apart the cell, and inner membrane and cytosolic constituents were 
separated by centrifugation. This modified procedure reduces the possibility of 
artifactual redistribution of antigens among the cell fractions.
Perhaps what P39 is “doing” in the outer envelope is important. What is P39 
bound to or complexed with in the outer envelope? As shown by immunoprecipitation, 
molecules associating with P39 in all four isolates include 50, 39, 15 and 13 kD. All 
noninfectious isolates had the following additional molecules: 60,46,38,22, and 21 
kD. In addition, isolate B31 had bands at 29 and 9 kD. Therefore there is a distinct 
difference in the molecules associating with P39 in infectious and noninfectious
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
72
isolates. One must note that P39’s association with other molecules may result in the 
masking o f the P39 epitope recognized by D1C9, therefore it is possible not all 
molecules interacting with P39 will be identified.
It also should be noted that the amount of a molecule contained within the outer 
envelope fraction is not necessarily indicative o f how much of that molecule is actually 
surface exposed. For example, in the western blot/densitometry analysis infectious 
B31 had the least amount of P39 in the outer envelope o f all the isolates, yet it had the 
highest flow cytometry reading for surface exposed P39. From these data it appears 
that all or most of the P39 in the outer envelope of infectious B31 is surface exposed.
In contrast, the infectious isolate CN40 flow cytometry analysis revealed that very little 
P39 is actually surface exposed. Indeed, the surface exposed P39 in high passage 
infectious CN40 was less than any other isolate either infectious or noninfectious. 
Either the P39 in CN40 outer envelope is located on the inner leaflet of the outer 
envelope thereby limiting surface exposure, or the P39 epitope is masked by another 
molecule at the cell surface.
Flow cytometry analysis also revealed that uncloned infectious isolates did 
have more P39 surface exposed than the corresponding noninfectious isolates as was 
seen in the western blot/densitometry analysis. Furthermore, infectious B31, JD1, and 
WCH1 had variable surface expression of P39. All exhibited broad, skewed peaks 
illustrating a lack of uniformity in P39 surface expression within the population of 
spirochetes. These same isolates did have more uniform reactivity in the noninfectious 
populations. Notably, all three uncloned populations exhibited the same shift from 
high P39 surface expression to low P39 surface expression. This may be due to a 
selection o f the lower expressing population over a period of time, or it may be due to a 
change in the expression of the P39 protein by all spirochetes within the population.
Another point to note is that surface protein expression can vary even within a 
cloned population as demonstrated by CN40 expression of OspA. Two distinct 
populations were detected by flow cytometry. In past research OspA expression has 
been demonstrated as being differentially regulated by temperature, but all cultures in 
this study were maintained at the same temperature. Therefore another regulatory
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mechanism must be involved. Another point is that uncloned isolates such as B31, 
WCH1 and JD1 can vary in surface expression of one molecule (P39) and yet have 
uniform expression in other surface exposed molecules (OspB and OspA). This also 
occurs for cloned isolate CN40, OspA expression is varied and yet P39 and OspB 
expression is uniform throughout the population. This varying of surface exposed 
molecules may be advantageous to the spirochete in evasion of immune responses. A 
recent study documenting Osp localization to both outer envelope and inner membrane 
fractions concluded that B.burgdorferi may uncouple lipoprotein expression from 
surface localization as part of their parasitic strategy for evasion of humoral immune 
response (102). This theory is supported in part by the findings in the present study; 
Osps located in both membrane fractions o f the spirochete, and a shift of location of 
surface exposed molecules by cloned and uncloned organisms. No immune pressure 
was placed on these organisms since they were grown in vitro, therefore the primary 
purpose for this shift may be entirely unrelated to immune evasion.
In the present study P39 was detected primarily in membrane fractions, 
therefore it would seem logical that P39 be hydrophobic. Since P39 was also detected 
in the cytosol of the uncloned isolates (most prominently in noninfectious B31), it 
raised the possibility that P39 may be modified in a way which would affect the 
solubility of the molecule. The solubility o f P39 has not previously been investigated. 
Other researchers utilizing Triton X I14 have reported a detergent soluble protein of 39 
kD obtained from isolate B31 (132), but did not confirm the identification of the 
molecule with a monoclonal antibody. The present study demonstrated, using western 
blot as confirmation, that P39 consistently localized to the detergent soluble fraction of 
B31 in all cell fractions tested. This was also the case for isolate CN40. This indicates 
P39 is hydrophobic in nature and does not exhibit any change in solubility from low to 
high passage or in different cell fractions. Therefore, the reason for the change of P39 
localization in infectious and noninfectious B31 is not due to a change in the solubility 
of the P39 molecule. P39 may be associating with additional molecules in B31, such 
as the 29 and 9 kD molecules seen in the immunoprecipitation experiment, and this
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may be responsible for the dramatic increase of P39 in the cytosol o f noninfectious 
B31.
There is a statistically significant relationship between P39 levels in the outer 
envelope o f a spirochete and the infectivity o f that spirochete. However, statistical 
significance does not necessarily translate into a cause and effect relationship in regards 
to infectivity. The only way to prove that P39 expression is required for the infectivity 
of B.burgdorferi is to create a P39-less mutant and assess the infectivity of that mutant.
Even if a P39-less mutant remained infectious, it could be used to assess the role of 
P39 in the pathology of Lyme disease. For this study an attempt was made to create a 
P39-less mutant B.burgdorferi. The use of electroporation and homologous 
recombination has previously been demonstrated as an effective route of genetic 
manipulation in B.burgdorferi (136). The first attempt consisted of creating a P39- 
LacZ fusion for use in electroporation. Despite much effort, no functional construct 
was obtained. The second attempt utilized a P39 deletion mutant construct; instead of 
inserting DNA as a mode of gene disruption, DNA was deleted. Screening by loss of 
P39 signal was not ideal but still an option. The transformation efficiency in 
B.burgdorferi using linear DNA is 103/1 g of DNA, therefore at least 2,000 of the 
10,000 electroporated organisms were expected to be successfully transformed under 
the conditions used. The putative transformants were screened both by ELISA and by 
western blot. No spirochetes could be detected which lacked expression of P39. It is 
possible that P39 is an essential protein for routine function of the bacterial cell and 
therefore any transformants carried a lethal mutation.
The changes in P39 localization of infectious and noninfectious organisms seen 
in this study may be indicative of a novel protein localization regulatory mechanism, 
operating in vivo. This regulation differs from the temperature regulation of OspA, and 
OspC; changes in temperature have no affect on the expression of P39 (105). The 
change in P39 localization seen in this study also differs from the antigenic variation 
seen in Borrelia hermsii, the causative agent of relapsing fever, which alters the 
expression of surface exposed lipoproteins by actual rearrangement o f the DNA. This
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novel change in P39 localization may explain B.burgdotferVs successful immune 
evasion in vivo. Clinical evidence shows the strong anti-P39 humoral response seen in 
an infected host fails to clear the B.burgdorferi infection. Yet P39 specific antibodies 
have been shown to be highly bactericidal in vitro (83). Perhaps P39 surface 
expression is required only during the initial establishment o f infection, and the surface 
exposure o f P39 facilitates development of the early P39 specific humoral response. It 
is possible that after the initial infection all or some of the spirochetes decrease the 
amount o f P39 that is surface exposed thereby evading the anti-P39 antibodies. This 
type o f regulation of surface exposed molecules may be the key to infectivity and to 
how B.burgdorferi successfully evade the hosts immune response.
In summary, this study provides groundwork information which is necessary 
for a more complete understanding of P39 and B.burgdorferi infectivity. The results of 
this study show that P39 is localized primarily to the outer envelope and inner 
membrane o f B.burgdorferi. Infectious isolates have a higher level of P39 in the outer 
envelope as compared to noninfectious isolates. P39 was shown to be hydrophobic in 
nature and this remained unchanged in all cell fractions o f infectious and noninfectious 
organisms. Other differences were noted between infectious and noninfectious isolates 
by silver stain, and immunoprecipitation. P39 associated with three molecules 
common to all isolates, and at least six additional molecules in noninfectious isolates 
only. And finally, P39 surface expression was found to change in all uncloned isolates 
during in vitro culture; uncloned isolates had a uniform decrease in surface expression 
of P39 which corresponded with their loss of infectivity.
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ANIMAL STUDIES
Approximately 32 female, B6CBA strain, Mus musculus, ages six to 12 weeks, 
were used in the following infectivity experiment. Mice were anesthetized with ether, 
and blood samples were collected from each mouse using the retro-orbital technique. 
Ether serves to minimize any pain the animals feel while blood is collected. Blood 
samples were required to monitor any serological changes that occur during the 
attempted infection process. Mice were inoculated with 0.1 ml of a Borrelia 
burgdorferi suspension (100,000 organisms). Two to eight mice were used per isolate 
(low or high passage). Fifteen days later mice received a 0.05 ml intraperitoneal 
injection of ketamine\xylazine solution. This causes the mice to sleep for 
approximately twenty minutes. At this time 10-15 Ixodes scapularis nymphs were 
allowed to feed on each mouse. Anesthetizing the mice allows the ticks a better 
opportunity to attach and feed on the mice. Unanesthetized mice will readily eat the 
ticks before they can attach. The ticks were used to determine if spirochetes can be 
transmitted from infected mice to ticks as occurs in the wild. Four days after feeding 
commences, the ticks were collected and held for processing. The mice were 
anesthetized with ether and bled by the retro-orbital technique for reasons already 
stated. The mice were euthanized by cervical dislocation (placing forceps at the base 
of the mouse's skull and giving a quick and strong jerk on the tail). This method results 
in complete ablation of central nervous system function and is approved by the Federal 
Guide for the Care and Use of Laboratory Animals. The tissues were collected and 
cultured in BSK-H media for detection o f B.burgdorferi.
Daily care for the animals was provided by the Animal Facility located in room 
406, Mills Godwin building. The use and treatment of the animals were approved by 
the Animal Care and Use Committee of Old Dominion University. A mammalian host 
was needed to determine the infectivity o f B.burgdorferi. Mice are reservoir hosts for 
B.burgdorferi in the wild, and are commonly used in laboratory studies
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
77
LITERATURE CITED
1. Steere, A.C., A.W. Malawista, J.A.Hardin, S. Ruddy, W. Askenase, W.A.
Andiman. 1977. Erythema chronicum migrans and Lyme arthritis: the 
enlarging clinical spectrum. Ann. Intern. Med. 86:685-689.
2. Steere, A.C., S.E. Malawista, D.R. Snydman. 1977. Lyme arthritis: an epidemic
of oligoarticular arthritis in children and adults in three Conneticut 
communities. Arthritis. Rheum. 20:7-17.
3. Steere, A.C., T.F. Broderick, S.E. Malawista. 1978. Erythema chronicum
migrans and Lyme arthritis: epidemiological evidence for a tick vector. Am. J. 
Epidemiol. 108:312-321.
4. Burgdorfer, W., A.G. Barbour, S.F. Hayes, J.L. Benach, E. Grunwalt, J.P.
Davis. 1982. Lyme disease: atick-bome spirochetosis? Science 216:1317- 
1319.
5. Steere, A.C., R.L. Grodziki, A.N. Komblatt, J.E. Craft, A.G. Barbour, W. 
Burgdorfer, G.P. Schmidt, E. Johnson, S.E. Malawista. 1983. The spirochetal 
etiology of Lyme disease. New Eng. J. Med. 308:733-742.
6. Dennis, D., R.Cambell. 1995. Lyme disease surveillance summary. Bacterial 
Zoonosis Branch, Division of Infectious Diseases, National Center for 
Infectious Diseases, Center for Disease Control and Prevention 6:1-12.
7. Moody, K.D., S. Barthold, G.A. Tergwilliger. 1990. Lyme borreliosis in 
laboratory animals: effect of host species and in vitro passage o f Borrelia 
burgdorferi. Am. J. Trop. Med. Hyg. 43:87-92.
8. Moody, K.D., S.W. Barthold, G.A. Terwilliger, D.S. Beck, G.M. Hansen, R.O. 
Jacoby. 1990. Experimental chronic Lyme borreliosis in Lewis rats. Am. J.
Trop. Med. Hyg. 42:165-174.
9. Barthold, S.W., D.H. Persing, A.L. Armstrong, R.A. Peeples. 1991. Kinetics of 
Borrelia burgdorferi dissemination and evolution of disease after intradermal 
inoculation of mice. Amer. J. of Path. 139:263-273.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
78
10. Shih, C., S.R. Telford, R.J. Pollack, A. Spielman. 1993. Rapid dissemination by 
the agent o f Lyme disease in hosts that permit fulminating infection. Infect. 
Immun. 61:2396-2399.
11. Sigal, L.H. 1995. Early disseminated Lyme disease:cardiac manifestations. 
Amer. J. Med. 98s:25-28.
12. Lesser, R.L. 1995. Ocular manifestations of Lyme disease. Amer. J. Med. 
98s:60-62.
13. Schaible, U.E., M.D. Kramer, C. Museteanu, G. Zimmer, H. Mossmann, and 
M.M. Simon. 1989. The severe combined immunodeficiency (scid) mouse. A 
laboratory model for the analysis of Lyme arthritis and carditis. J. Exp. Med. 
170:1427-1432.
14. Pachner, A.R. 1995. Early disseminated Lyme disease:Lyme meningitis. Amer. 
J. Med. 98s:30-41.
15. Ilowite, N.T. 1995. Muscle, reticuloendothelial, and late skin manifestations of 
Lyme disease. Amer. J. Med. 98s:63-68.
16. Nadelman, R.B., G.P. Wormser. 1995. Erythema migrans and early Lyme 
disease. Amer. J. Med. 98s: 15-24.
17. Balmelli, T., J.C. Piffaretti. 1995. Association between different clinical 
manifestations of Lyme disease and different species of Borrelia burgdorferi 
sensu lato. Res. Microbiol. 146:329-340.
18. Barbour, A.G., D. Fish. 1993. The biological and social phenomenon of Lyme 
disease. Science 260:1610-1616.
19. Steere, A.C. 1989. Lyme disease. New Eng. J. Med.321:586-596.
20. Pachner, A.R.. 1989. Neurologic manifestations of Lyme disease, the new 
"great imitator." Rev. Infect. Dis.Suppl.l 1:1482-1484.
21. Steere, A.C., S.E. Malawista, N.H. Bartenhagen, P.N. Spieler, J.H. Newman, 
D.W. Rahn, G.J. Hutchinson, J. Green, D.R. Snydman, E. Taylor. 1984. The 
clinical spectrum and treatment of Lyme disease. Yale J. Biol. Med. 57:453- 
461.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
79
22. Magnarelli, L.A. 1995. Current status of laboratory diagnosis of Lyme disease. 
Amer. J. Med. 98s: 10-14.
23. Steere, A.C. 1984. Conference Summary. Yale J. Biol. Med. 57:711-713.
24. Simpson, W.J., W. Burgdorfer, M.E. Schrumpf, R.H. Karstens, T.G. Schwan.
1991. Antibody to a 39-Kilodalton Borrelia burgdorferi antigen (P39) as a 
marker for infection in experimentally and naturally inoculated animals. J. Clin. 
Microbiol. 29:236-242.
25. Russel, H., J.S. Sampson, G.P. Schmid, H.W. Wilkinson, B. Plikaytis. 1984. 
Enzyme-linked immunosorbent assay and indirect immunofluorescence assay 
for Lyme disease. J. Infect. Dis. 149:465-469.
26. Craft, J.E., R.L. Grodzick, A.C. Steere. 1984. Antibody response in Lyme 
disease; evaluation of diagnostic tests. J. Infect. Dis. 149:789-794.
27. Dennis, D., R.Cambell. 1995. Lyme disease surveillance summary. Second 
National Conference on Serologic Diagnosis of Lyme Disease. 6:1-12.
28. Steere, A.C., G.J. Hutchinson, D.W. Rawn. 1983. Treatment of the early 
manifestations of Lyme disease. Ann. Intern. Med. 99:22-25.
29. Philipson, A. 1991. Antibiotic treatment in Lyme borreliosis. Scand. J. Infect. 
Dis.-Suppl. 77:145-150.
30. Sigal, L. 1992. Current recomendations for the treatment of Lyme disease. 
Drugs 43:683-699.
31. Steere, A.C. 1995. Musculoskeletal manifestations of Lyme disease. Amer. J. 
Med. 98s:44-51.
32. Johnson, R.C., and C.A. Norton Hughes. 1991. The genus Borrelia. The 
Prokaryotes 3:3561-3563.
33. Szczepanski, A., and J.L. Benach. 1991. Lyme borreliosis: host responses to 
Borrelia burgdorferi. Microbiol. Rev. 55:21-34.
34. Sigal, L.H., and A.H. Tatum. 1995 Lyme disease patients serum contains IgM 
antibodies to Borrelia burgdorferi that cross react with neuronal antigens. 
Neurol. 38:1439-1442.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
80
35. Aberer, E., C. Brunner, G. Suchanek, H. Klade, A.G. Barbour, G. Stanek, H. 
Lassman. 1989. Molecular mimicry and Lyme borreliosis: shared antigenic 
determinants between Borrelia burgdorferi and human tissue. Ann. Neurol. 
26:732-737.
36. Simon, M.M., U.E. Schaible, R. Wallich, M.D. Kramer. 1991. A mouse model 
for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease. 
Immun. Today.l2:l 1-16.
37. Fikrig, E., S.W. Barthold, F.S. Kantor, R.A. Flavell. 1990. Protection of mice 
against the Lyme disease agent by immunization with recombinant Osp A. 
Science 250:553-556.
38. Schaible, U.E., M.D. Kramer, K. Eichmann, M. Modolell, C. Museteanu, M.M. 
Simon. 1990. Monoclonal antibodies specific for the outer surface protein A 
(OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined 
immunodeficiency (scid) mice. Proc. Natl. Acad. Sci. USA 87:3768-3772.
39. Stover, C.K., G.P. Bansal, M. Hanson, J.E. Burlein, S.R. Palaszynski, J.F. 
Young, A. Sadziene, A.G. Barbour. 1993. Protective immunity elicited by 
recombinant Bacille Calmette-Guerin (BCG) expressing outer surface protein 
A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 
178:197-209.
40. Fikrig, E., S.R. Telford, S.W. Barthold, F.S. Kantor, A. Spielman, and R.A. 
Flavell. 1992. Elimination of Borrelia burgdorferi from vector ticks feeding on 
OspA-immunized mice. Proc. Natl. Acad. Sci. USA 89:5418-5421.
41. de silva, A.M., S.R. Telford, L.R. Burnet, S.W. Barthold, E. Fikrig. 1996. 
Borrelia burgdorferi OspA is an arthropod specific transmission-blocking 
Lyme disease vaccine. J. Exp. Med. 183:271-275.
42. Burgdorfer, W., S.F. Hayes, D. Corwin. 1989. Pathophysiology o f the Lyme 
disease spirochete, Borrelia burgdorferi, in Ixodid ticks. Rev. Infect. Dis. vol 
II Suppl. 6:1442-1450.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
81
43. Ribiero, M.C., T.N. Mather, J. Piesman, A. Spielman. 1987. Dissemination and 
salivary delivery of Lyme disease spirochetes in vector ticks (Acari: Ixodidae). 
J. Med. Entomol. 24:201-205.
44. Piesman, J. 1995. Dispersal o f the Lyme disease spirochete Borrelia 
burgdorferi to the salivary glands of feeding nymphal Ixodes scapularis 
(Acari:Ixodidae). J. Med. Entomol. 32:519-521.
45. Schaible, U.E., R. Wallich, M.D. Kramer, L. Gem, J.F. Anderson, C. 
Musteteanu, M.M. Simon. 1993. Immune sera to individual Borrelia 
burgdorferi isolates or recombinant OspA therof protects SCID mice against 
infection with homologous strains but only partially or not at all against those 
of different OspA/OspB genotype. Vaccine 11:1049-1054.
46. Lam, T.T., T.K. Nguyen, R.R. Montgomery, F.S. Kantor, E. Fikrig, R.A. 
Flavell. 1994. Outer surface proteins E and F of Borrelia burgdorferi, the agent 
of Lyme disease. Infect. Immun. 62:290-298.
47. Nguyen, T.K., T.T. Lam, S.W. Barthold, S.R. Telford ID, R.A. Flavell, E. 
Fikrig. 1994. Partial destruction of Borrelia burgdorferi within ticks engorged 
on OspE- or OspF-immunized mice. Infect. Immun. 62:2079-2084.
48. Probert, W.S., and R.B. LeFebvre. 1994. Protection of C3H/HeN mice from 
challenge with Borrelia burgdorferi through active immunization with OspA, 
OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect. Immun. 
62:1920-1926.
49. Bergstrom, S., A.G. Barbour, C.F. Garon, P. Hindersson, I. Saint Girons, T.G. 
Schwan. 1991. Genetics of Borrelia burgdorferi. Scand. J. Infect. Dis. Suppl. 
77:103-105. 55.
50. Spielman, A, M.L. Wilson, J.F. Levine, J. Piesman. 1985. Ecology of Ixodes 
dammini-bome human babeseosis and Lyme disease. Ann. Rev. Entomol. 
30:439-460.
51. Fingerle, V., U. Hauser, G. Liegl, B. Petko, V. Preac-Mursic, B. Wilske. 1995. 
Expression of outer surface proteins A and C of Borrelia burgdorferi in Ixodes 
ricinus. J. Clin. Microbiol. 33:1867-1869.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8 2
52. Brunet, L.R., A. Spielman, S.R. Telford HI. 1995. Short report:density o f Lyme 
disease spirochete within deer ticks collected from zoonotic sites. Amer. J. 
Trop. Med. Hyg. 53:300-302.
53. Piesman, J., T.N. Mather, R.J. Sinsky, A. Spielman. 1987. Duration of tick 
attachment and Borrelia burgdorferi transmission. J. of Clin. Microbiol. 
25:557-558.
54. Benach, J.L., J.L. Coleman, R.A. Skinner, E.M. Bosler. 1987. Adult Ixodes 
dammini on rabbits: a hypothesis for the development and transmission of 
Borrelia burgdorferi. J. Infect. Dis. 155:1300-1306.
55. Kimsey, R.B., A. Spielman. 1990. Motility o f  the Lyme disease spirochete in 
fluids as viscous as the extracellular matrix. J. Infect Dis. 162:1205-1208.
56. Comstock, L.E., and D.D. Thomas. 1989. Penetration of endothelial cell 
monolayers by Borrelia burgdorferi. Infect. Immun. 57:1626-1628.
57. Kurtti, T.J., U.G. Munderloh, G.G. Ahlstrand, R.C. Johnson. 1988. Borrelia 
burgdorferi in tick cell culture: growth and cellular adherence. J. Med.
Entomol. 25:256-261.
58. Hechemy, K.E., W.A. Samsonoff, M. McKee, J.M. Guttman. 1989. Borrelia 
burgdorferi attachment to mammalian cells. J. Infect. Dis. 159:805-806.
59. Guo, B.P., S.J. Norris, L.C. Rosenberg, M. Hook. 1995. Adherence of Borrelia 
burgdorferi to the proteoglycan decorin. Infect. Immun. 63:3467-3473.
60. Szczepanski, A., M.B. Furie, J.L. Benach, B.P. Lane, H.B.Fleit. 1990. 
Interaction between Borrelia burgdorferi and endothelium in vitro. J. Clin. 
Invest. 85:1637-1647.
61. Garcia-Monco, J.C., B. Femandez-Villar, J.C. Allen, J.L.Benach. 1990.
Borrelia burgdorferi in the central nervous system:experimental and clinical 
evidence for early invasion. J. Infect. Dis. 161:1187-1193.
62. Barthold, S.W., M.S. de Souza, J.L. Janotka, A.L. Smith, and D.H. Persing. 
1993. Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 
143:959-971.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
83
63. Piesman, J., J.R. Oliver, RJ. Sinsky. 1990. Growth kinetics of the Lyme 
disease spirochete (Borrelia burgdorferi) in vector ticks (Ixodes dammini).
Am. J. Trop. Med. Hyg. 42:352-357. -
64. Gem, L., U.E. Schaible, M.M. Simon. 1993. Mode o f inoculation of the Lyme 
disease agent Borrelia burgdorferi influences infection and immune responses 
in inbred strains o f mice. J. Infect. Dis. 167:971-975.
65. Schwan, T.G., W. Burgdorfer, C.F. Garon. 1988. Changes in infectivity and 
plasmid profile in the Lyme disease spirochete, Borrelia burgdorferi, as a result 
of in vitro cultivation. Infect. Immun. 56:1831-1836.
66. Hughes, C.A., S.M. Engstrom, L.A. Coleman, C.B. Kodner, R.C. Johnson.
1993. Protective immunity is induced by a Borrelia burgdorferi mutant that 
lacks OspA and OspB. Infect. Immun. 61:5115-5122.
67. Johnson, R.C., N. Marek, and C. Kodner. 1984. Infection of Syrian hamsters 
with the Lyme disease spirochetes. J. Clin. Microbiol. 20:1099-1101.
68. Schwan, T.G., R.H. Karstens, M.E. Schrumpf, W.J. Simpson. 1990. Changes in 
antigenic reactivity of Borrelia burgdorferi, the Lyme disease spirochete, 
during persistent infection in mice. Can. J. Microbiol. 37:450-454.
69. Schwan, T.G., W. Burgdorfer, M.E. Schrumpf, R.H. Karstens. 1988. The 
urinary bladder, a consistent source of Borrelia burgdorferi in experimentally 
infected white-footed mice (Peromyscus leucopus). J. Clin. Microbiol. 26:893- 
895.
70. Gem, L., U.E. Schaible, M.M. Simon. 1993. Mode o f inoculation of the Lyme 
disease agent Borrelia burgdorferi influences infection and immune responses 
in inbred strains o f mice. J. Infect. Dis. 167:971-975.
71. Johnson, R.C., C. Kodner, M. Russel, P.H. Duray. 1988. Experimental 
infection of the hamster with Borrelia burgdorferi. Ann. NY Acad. Sci. 
539:258-263.
72. Barthold, S.W., D.S. Beck, G.M. Hansen, G.A. Terwilliger, K.D. Moody. 1990. 
Lyme borreliosis in selected strains and ages of laboratory mice. J. Infect. Dis. 
162:133-138.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
84
73. Schwan,T.G., W.Burgdorfer. 1987. Antigenic changes of Borrelia burgdorferi 
as a result o f in vitro cultivation. J. Infect. Dis. 156:852-858.
74. Simpson, W.J., M.E. Schrumpf, T.G. Schwan. 1990. Reactivity o f human 
Lyme borreliosis sera with a 39-kilodalton antigen specific to Borrelia 
burgdorferi. J. Clin. Microbiol. 28:1329-1337.
75. Norris, S.J., C.J. Carter, J.K. Howell, A.G. Barbour. 1992. Low passage 
associated proteins o f Borrelia burgdorferi B31: characterization and molecular 
cloning of Osp D, a surface-exposed, plasmid encoded lipoprotein. Infect. 
Immun. 60:4662-4672.
76. Simpson, W.J., C.F. Garon, T.G. Schwan. 1990. Analysis of supercoiled 
circular plasmids in infectious and non-infectious Borrelia burgdorferi.
Microb. Path. 8:109-118.
77. Norris, S.J., J.K. Howell, S.A. Garza, M.S. Ferdows, A.G. Barbour. 1995.
High- and low- infectivity phenotypes of clonal populations of in vitro-cultured 
Borrelia burgdorferi. Infect. Immun. 63:2206-2212.
78. Pachner, A.R., J. Basta, E. Delany, D. Hulinska. 1995. Locaization of Borrelia 
burgdorferi in murine Lyme borreliosis by electron microscopy. Amer. J.
Trop. Med. Hyg. 52:128-133.
79. Schwan, T.G., W.J. Simpson. 1991. Factors influencing the antigenic reactivity 
of Borrelia burgdorferi, the Lyme disease spirochete. Scand. J. Infect. Dis. 
Suppl. 77:94-101. 86. Dorward, D.W., E.D. Huguenel, G. Davis, C.F. Garon. 
1992. Interactions between extracellular Borrelia burgdorferi proteins and non- 
Borrelia-directed immunoglobulin M antibodies. Infect. Immun. 60:838-844.
80. Schaible, U.E., M.D. Kramer, R. Wallich, T.Tran, M.M. Simon. 1991. 
Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody 
response and and association of H-2 genes with resistance and suseptibility to 
development of arthritis. Eur. J. Immunol.21:2397-2405.
82. Benach, J.L., H.B. Fleit, G.S. Habicht, J.L. Coleman, E. Boseler, B.P. Lane.
1984. Interactions of phagocytes with the Lyme disease spirochete: role of the 
Fc receptor. J. Infect. Dis. 150:497-507.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
85
83. Scriba, M., J.S. Ebrahim, T. Schlott, H. EifFert. 1993. The 39-kilodaIton protein 
of Borrelia burgdorferi: a target for bacterialcidal human monoclonal 
antibodies. Infect. Immun. 61:4523-4526.
84. Barthold, S.W.. 1993. Antigenic stability of Borrelia burgdorferi during 
chronic infections of immunocompetent mice. Infect. Immun. 61:4955-4961.
85. Barbour, A.G. 1991. Molecular biology of antigenic variation in Lyme 
borreliosis and relapsing fever: a comparative analysis. Scand. J. Infect. Dis. 
Suppl. 77:88-93.
86. Dorward, D.W., E.D. Huguenel, G. Davis, C.F. Garon. 1992. Interactions 
between extracellular Borrelia burgdorferi proteins and non-Z?orre//a-directed 
immunoglobulin M antibodies. Infect. Immun. 60:838.
87. Johnson, R.C., G.P. Schmidt, F.W. Hyde, A.G. Steigerwald, D.J. Brenner.
1984. Borrelia burgdorferi sp. nov.:Etiologic agent of Lyme disease. Int. J. 
Syst. Bacteriol. 34:436-497.
88. Marconi, R.T., L. Lubke, W. Hauglum,~C.F. Garon. 1992. Species-specific 
identification of and distinction between Borrelia burgdorferi genomic groups 
by using 16s rRNA-directed oligonucleotide probes. J. Clin. Microbiol. 30:628- 
632.
89. Baranton, G., D. Postic, I. Saint Girons, P. Boerlin, J. Piffaretti, M. Assous, 
P.A.D. Girmont. 1992. Delineation of Borrelia burgdorferi sensu stricto, 
Borrelia garinii, sp. nov. and Group VS461 associated with Lyme borreliosis. 
Int. J. Syst. Bacteriol. 42:378-383.
90. Canica, M.M., F. Nato, L. duMerle, J.C. Mazic, G. Baranton, D. Postic. 1993. 
Monoclonal antibodies for identification of Borrelia ajzelii sp. nov. associated 
with late cutaneous manifestations of Lyme borreliosis. Scand. J. Infect. Dis. 
25:441-448.
91. Dykhuizen, D.E., D.S. Polin, J.J. Dunn, B. Wilske, V. Preac-Mursic, R.J. 
Dattwyler, B.J. Luft. 1993. Borrelia burgdorferi is clonaklmplications for 
taxonomy and vaccine development. Proc. Natl. Acad. Sci. USA. 90:10163- 
10167.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8 6
92. Baraton, G., D. Postic, I. Saint Girons, P. Borelin, J.C. Piffaretti, M. Assous,
P. A. Grimont. 1992. Delineation of Borrelia burgdorferi sensu stricto, Borrelia 
garinrti sp. nov., and Group VS461 associated with Lyme borreliosis. Int. J. 
Syst. Bacteriol. 42:378-383.
93. Wilske, B., J.F. Anderson, G. Baranton, A.G. Barbour, K. Hovind-Hougan, 
R.C. Johnson, V. Preac-Mursic. 1991. Taxonomy of Borrelia spp.. Scand. J. 
Infect. Dis. Suppl. 77:108-129.
94. Takayama, K., R.J. Rothenberg, A.G. Barbour. 1987. Absence of 
lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi.
Infect. Immun. 55:2311-2313.
95. Belisle, J.T., M.E. Brandt, J.D. Randolf, M.V. Norgard. 1994. Fatty acids of 
Treponema pallidum and Borrelia burgdorferi lipoproteins. J. Bacteriol. 
176:2151-2157.
96. Randolf, J.D., M.S. Goldberg, K. Bourell, S.I. Baker, J.D. Jones, M.V.
Norgard. 1995. Characterization o f outer membranes isolated from Borrelia 
burgdorferi, the Lyme disease spirochete. Infect. Immun. 63:2154-2163.
97. Brandt, M.E., B.S. Riley, J.D. Randolf, M.V. Norgard. 1990. Immunogenic 
integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect. 
Immun. 58:983-991.
98. Randolf, J.D., K.W. Bourell, D.R. Akins, J.S. Brusca, M.V. Norgard. 1994. 
Analysis o f Borrelia burgdorferi membrane architecture by freeze-fracture 
electron microscopy. J. Bacteriol. 176:21-31.
99. Luft, J.L., W. Jiang, P. Munoz, R.J. Dattwyler, P.D. Gorevic. 1989. 
Biochemical and immunological characterization of the surface proteins of 
Borrelia burgdorferi. Infect. Immun. 57:3637-3645.81.
100. Bergstrom, S., V.G. Bundoc, A.G. Barbour. 1989. Molecular analysis of linear 
plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease 
spirochete Borrelia burgdorferi. Mol. Microbiol. 3:479-486.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
87
101. Fuchs, R., S. Jauris, F. Lottspeich, V. Preac-mursic, B. Wilske, E. Soutschek.
1992. Molecular analysis and expression of a Borrelia burgdorferi gene 
encoding a 22kDa protein (pC) in Escherichia coli. Mol. Microbiol. 6:503-509.
102. Cox, D.L., D.R. Akins, K.W. Bourell, P. Lahdenne, M.V. Norgard. 1996. 
Limited surface exposure of Borrelia burgdorferi outer surface lipoproteins. 
Proc. Natl. Acad. Sci. USA. 93:7973-7978.
103. Barbour, A. G., R.A. Heiland, T.R. Rowe. 1985. Heterogeneity of major 
proteins in Lyme disease Borreliae: A molecular analysis o f North American 
and European isolates. J. Infect. Dis. 152:478-484.
104. Barbour, A.G., Tessier S.L., S.F. Hayes. 1984. Variation in a major surface 
protein of Lyme disease spirochetes. Infect. Immun. 45:94-100.
105. Stevenson, B., T.G. Schwan, P.A. Rosa. 1995. Temperature related differential 
expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi. 
Infect. Immun. 63:4535-4539.
106. Schwan, T.G., J. Piesman, W.T. Golde, M.C. Dolan, P.A. Rosa. 1995. 
Induction of an outer surface protein on- Borrelia burgdorferi during tick 
feeding. Proc. Nat. Acad. Sci. USA 92:2909-2913.
107. Comstock, J.L., E. Fikrig, R.J. Shoberg, R.A. Flavell, D.D. Thomas. 1992. 
Monoclonal antibodies to OspA inhibits association o f Borrelia burgdorferi 
with human endothelial cells. Infect. Immun. 61:423-431.
108. Sadziene, A., A.G. Barbour, P.A. Rosa, D.D. Thomas. 1993. An OspB mutant 
o f Borrelia burgdorferi has reduced invasiveness in vitro and reduced 
infectivity in vivo. Infect. Immun. 61:3590-3596.
109. Sadziene, A., D.D. Thomas, A.G. Barbour. 1995. Borrelia burgdorferi mutant 
lacking Osp:biological and immunological characterization. Infect. Immun. 
63:1573-1580.
110. Ramamoorthy, R., L. Povinelli, M.T. Philipp. 1996. Molecular characterization, 
genomic arrangement, and expression of bmpD, a new member of the bmp 
class of genes encoding membrane proteins of Borrelia burgdorferi. Infect. 
Immun. 64:1259-1264.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8 8
111. Golde, W.T., M.C. Dolan. 1995. Variation in antigenicity and infectivity of 
derivatives o f Borrelia burgdorferi, strain B31, maintained in the natural, 
zoonotic cycle compared with maintainance in culture. Infect. Immun. 63:4795- 
4801.
112. Simpson, W.J., W. Cieplak, M.E. Schrumpf, A.G. Barbour, T.G. Schwan.
1994. Nucleotide sequence and analysis o f the gene in Borrelia burgdorferi 
encoding the immunogenic P39 antigen. FEMS Microbiol. Letters 119:381- 
388.
113. Charon, N.W., E.P. Greenberg. 1992. Spirochete chemotaxis, motility, and the 
structure o f the spirochetal periplasmic flagella Res. Microbiol. 143:597-603.
114. Goldstein, S.F., N.W. Charon, J.A. Kreiling. 1994. Borrelia burgdorferi swims 
with a planar waveform similar to that of eukaryotic flagella Proc. Natl. Acad 
Sci. 91:3433-3437.
115. Barbour, A.G. 1988. Plasmid analysis o f Borrelia burgdorferi, the Lyme 
disease agent. J. Clin. Microbiol. 26:475-478.
116. Hinnebusch, J., A.G. Barbour. 1992. Linear- and circular- plasmid copy 
number in Borrelia burgdorferi. J. Bacteriol. 174:5251-5257.
117. Carroll, J.A., F.C. Gherardini. 1996. Membrane protein variations associated 
with in vitro passage of Borrelia burgdorferi. Infect. Immun. 64:392-398.
118. Davidson, B.S., J. MacDougall, I. Saint Girons. 1992. Physical map of the 
linear chromosome of Borrelia burgdorferi 212, the causative agent o f Lyme 
disease, and localization of rRNA genes. J. Bacteriol. 174:3766-3774.
119. Ferdows, M.S., A.G. Barbour. 1989. Megabase-sized linear DNA in the 
bacterium Borrelia burgdorferi, the Lyme disease agent. Proc. Natl. Acad. Sci. 
USA 86:5969-5973.
120. Sullivan, T.J., K.E. Hechemy, H.L. Harris, U.H. Rudofsky, W.A. SamsonofF, 
A.J. Peterson, B.D. Evans, S.L. Balaban. 1994. Monoclonal antibody to native 
P39 protein from Borrelia burgdorferi. J. Clin. Microbiol. 32:423-429.
121. Barthold, S.W., K.D. Moody, G.A. Twillinger, R.O. Jacoby, A.C. Steere. 1988. 
An animal model for Lyme arthritis. Ann. N.Y. Acad. Sci. 539:264-273.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
89
122. Pachner, A.R., N. Ricalton, and E. Delany. 1993. Comparison of polymerase 
chain reaction with culture and serology for diagnosis o f murine experimental 
Lyme borreliosis. J. Clin. Microbiol. 31:208-214.
123. Rosa, P.A., D. Hogan, T.G. Schwan. 1991. Polymerase chain reaction analyses 
identify two distinct classes of Borrelia burgdorferi. J. Clin. Microbiol. 
29:524-532.
124. Adam, T., G.S. Gassmann, C. Rasiah, U.B. Gobel. 1991. Phenotypic and 
Genotypic analysis of Borrelia burgdorferi isolates from various sources. 
Infect. Immun. 59:2579-2585.
125. Rosa, P.A., T.G. Schwan. 1989. A specific and sensitive assay for the Lyme 
disease spirochete Borrelia burgdorferi using the polymerase chain reaction. J. 
Infect. Dis. 160:1018-1024.
126. Barbour, A.G., S.L. Tessier, W.J. Todd. 1983. Lyme disease spirochetes and 
Ixodid tick spirochetes share a common surface antigenic determinant defined 
by a monoclonal antibody. Infect. Immun. 41:795-804.
127. Brusca, J.S., A.W. McDowall, M.V. Norgard, J.D. Randolf. 1991. Localization 
o f outer surface proteins A and B in both the outer membrane and intracellular 
compartments of Borrelia burgdorferi. J. Bacteriol. 173:8004-8008.
128. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227:680-685.
129. Ochs, D.C., E.H. McConkey, D.W. Sammons. 1981. Staining methodology. 
Electrophoresis 2:304.
130. Promega Corporation. Madison, WI. 1993. Promega Protein Guide: Tips and 
Techniques. 1:3-6.
131. Bundoc, V.G., A.G. Barbour. 1989. Clonal polymorphisms of outer membrane 
protein OspB of Borrelia burgdorferi. Infect. Immun. 57:2733-2741.
132. Cunningham, T.M., D.D. Thomas, S.D. Thompson, J.N. Miller, M.A. Lovett. 
1988. Identification o f Borrelia burgdorferi surface components by Triton X- 
114 phase partitioning. Ann. N.Y. Acad. Sci. 539:376-378.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
90
133. Bledsoe, H.A., J.A. Carroll, T.R. Whelchel, M.A. Fanner, D.W. Dorward, F.C. 
Gherardini. 1994. Isolation and Partial characterization of Borrelia burgdorferi 
inner and outer membranes by using isopycnic centrifugation. J. Bacteriol. 
176:7447-7455.
134. Bordier, C. 1981. Phase seperation of integral membrane proteins in Triton X- 
114 solution. J. Biol. Chem. 256:1604-1607.
135. Pryde, J.G.. 1986. Triton X-l 14: a detergent that has come in from the cold. 
TIBS 11:160-163.
136. Samuels, S.D. 1995. Electrotransformation of the spirochete Borrelia 
burgdorferi. Methods Molec. Biol. 47:253-259.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX







Appendix 1. Plasmid map of 
pSPR33. P39 gene, bmpB gene, 
ampicillin resistance gene, and 
restriction sites are shown.






Appendix 2. Plasmid map of 
pCH110. LacZ gene, ampicillin 
resistance gene, and restriction 
sites are shown.
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Appendix 3. W estern blot densitometry assessment. Densitometry absorbance 
readings from a western blot o f serial dilutions of B. burgdorferi (protein concentration 
given in pg) developed with monocionals specific for P39 ( • ) ,  Osp A (♦) and Osp B (■).
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